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Abstract: Vaccination programs generate direct protection, herd 
protection and, occasionally, side effects, distributed over different 
age groups. This study elicits the general public's view on how to 
balance these outcomes in funding decisions for vaccines. We performed an 
optimal design discrete choice experiment with partial profiles in a 
representative sample (N=1499) of the public in the United Kingdom. Using 
a panel mixed logit model, we quantified, for four different types of 
infectious disease, the importance of a person's age during disease, how 
disease was prevented—via direct vaccine protection or herd protection—
and whether the vaccine induced side effects. Our study shows clear 
patterns in how the public values vaccination programs. These diverge 
from the assumptions made in public health and cost-effectiveness models 
that inform decision-making. We found that side effects and infections in 
newborns and children were of primary importance to the perceived value 
of a vaccination program. Averting side effects was, in any age group, 
weighted three times as important as preventing an identical natural 
infection in a child whereas the latter was weighted six times as 
important as preventing the same infection in elderly aged 65-75 years. 
These findings were independent of the length or severity of the disease, 
and were robust across respondents' backgrounds. We summarize these 






Reply to reviewers 
 
 
We would like to thank both reviewers for their extensive and constructive feedback. This has 
substantially improved our paper. Below we respond point-by-point to their comments.  
 
Reviewer #1: SSM-D-18-01397 
 
Quantifying the public's view on social value judgements in vaccine decision making-a discrete choice 
experiment I've read with great interest the manuscript "Quantifying the public's view on social value 
judgements in vaccine decision making: a discrete choice experiment". The manuscript starts with 
describing that the usual framework of cost-effectiveness analysis does not consider alternatives 
regarding the public's view on value judgements in vaccine decision making. The authors have 
performed a discrete choice experiment in order to examine the importance of different age groups in 
the program's overall evaluation and the extent to which it matters whether these age groups are 
affected by either direct, herd or side effects. By quantifying these preferences and translating these 
into preference weights for health outcomes, they hope to incorporate these into a future economic 
evaluation framework. The choice experiment was conducted among a representative sample, 
recruited from a commercial panel, in the UK. Five attributes were chosen: direct effects of 
vaccination, targeted age of the vaccination programme, side effects related to vaccination, herd 
effects, the age group affected by the herd effects. It was an unlabelled design. The diseases were 
also unnamed but described based on the dimensions and level of the EQ-5D-3L. Four different 
disease profiles were presented: severe( lasting nine days), severe ( lasting sixty days), mild (lasting 
nine days) and mild (lasting sixty days). The design was a D-optimal in a Bayesian framework. Results 
showed that vaccine induced side-effects and infections in young children were considered the most 
important when assessing a program's value. Averting side-effects of the vaccine was weighted three 
times that of preventing an identical natural infection in any age groups. Vaccination programs that 
prevent disease in children were weighted six times that of programmes preventing a disease in older 
adults.   
As I've said before, I've read the manuscript with great interest and thought the manuscript was 
overall well written. However, I think the manuscript could benefit from a more in-depth and 
thorough explanation of not only the process of selecting the attributes/levels but also the discussion 
of the results. 
 




 The authors state that the CEA framework neglects key value judgements needed to evaluate 
vaccine programmes. Although they refer to a multiple of references, I would like to see a 
concrete example of which key values are missing and how this is taken into consideration 
within this discrete choice experiment.  
 
Reply: We agree that the development of the specific research question in the introduction was 
insufficiently clear and also insufficiently focused towards the concrete context of vaccines. It was 
also  not entirely clear how our DCE provided answers to these problems. We have rewritten parts 
of the introduction to make it more focused and concrete, including examples and we have added 
a starting paragraph before the methods section to explain how our DCE can provide answers.  
 
In the introduction: 
“There is a growing literature about the limits of CEA in assessing the value of vaccination [9-15].  
Response to Reviewers* (NO AUTHOR DETAILS)
One important criticism is that CEA is limited in how it values the consequences of vaccination. 
Summary outcome measures [such as e.g. infections prevented or Quality-Adjusted Life Years 
(QALYs) gained] neglect the particular social context in which these outcomes occur. Nonetheless, 
such contextual features are important aspects to consider when evaluating a vaccination strategy 
[….]  There are qualitative differences between these direct, herd and side effects. Creating herd 
protection can be of particular ethical value (e.g. to protect vulnerable groups who otherwise 
cannot protect themselves) and there is a profound psychological impact of vaccine-induced side 
effects. Moreover, the distribution of these three different effect types over different age groups is 
important. […] Several notable examples illustrate that this broader social context of health 
outcomes needs to be considered in vaccine decision-making [18]. For instance, vaccines against 
rotavirus (Rotashield®) and pertussis (whole cell pertussis vaccine) were withdrawn from many 
countries because of a perceived risk of side effects, even though from a medical perspective the 
benefit from vaccination largely outweighed any potential risk [19-21]. Also, despite persuasive 
economic and public health benefits of childhood influenza vaccination, few countries have 
actually implemented such a preventive strategy, due in large part to concerns about the social 
acceptability and equity of targeting vaccination at children to protect the wider population [22]. 
And, in many countries introduction of an effective varicella vaccination program has been delayed 
because of concerns about the possible ‘exogenous boosting effect’ and its social repercussions, 
i.e. that reduced chickenpox transmission among children (due to varicella vaccination) might 
temporarily increase shingles incidence among older generations [23]. Misjudging ethical norms 
and social sensitivities in vaccination policy by over-relying on CEA can have important 
implications…” 
 
In the methods: 
“DCEs are a widely used survey method to quantify individuals’ preferences [35, 36] (for a general 
review of applications, see [37]). Participants are presented with a series of choices, usually 
between two goods described by the same attributes but differing in their attribute levels. By 
observing respondents’ preferred choices, researchers can infer how the value of the competing 
options is determined by the attributes of the product. In our case, we observe how people 
prioritize between vaccination programs based on the number of direct, herd and side effects 
generated by the program, and their distribution over different age groups. This allows us to 
estimate a utility function that describes how the public values vaccination programs, taking into 
account the different types of vaccine effect and their distribution.” 
 
Methods:  
 I miss a clear description of the selection of the attributes and the levels. Why were these 
specific 5 attributes chosen?   
 
Reply: This is an important point and it is in fact a substantial part of the work we did for this DCE. 
We agree that this aspect of the DCE should be more extensively described in the paper. We have 
now included more motivating discussion regarding the choice of attributes and levels.  
 
“To develop the final attributes and levels of the vaccine programs included in the DCE, we 
followed a three stage iterative process. We performed a literature search of other vaccine-related 
DCEs to assess the choice context and which attributes and levels were considered. These 
attributes were disease incidence, case fatality risk, economic impact, duration of illness and 
duration of vaccine protection, severity of illness and severity of side effects, and various personal 
characteristics including age, gender and willingness/ability to get vaccinated. [40-44] From this 
list, we took the combination of attributes that was, in combination with the four disease profiles, 
best suited to answer our research question. We presented several versions to a convenience 
sample of lay persons, colleagues and collaborators at the market research company in a pilot 
questionnaire, which we revised in response to received comments. We re-iterated this process 
until we found the right form for the DCE from which, with a relatively simple set of in total five 
core attributes (Table 1), we could robustly calculate preference weights.” 
 
“After the design, we tested our survey among a pilot sample of the online panel (N=69) to confirm 
that respondents could fully understand and complete the survey. Based on the feedback from this 





 How realistic is it that the side effects were presented as identical to an episode of the disease 
a vaccine usually prevents? For me, it is not clear although the authors partly explain this in 
the discussion. However, the whole issue nowadays is that an increasing number of people 
think the benefit of a vaccine (i.e. preventing the disease) does not outweigh the "perceived" 
risks of the vaccine itself. This leads to a reduced uptake with potentially devastating 
consequences. My point is: how valid are the results of this study if the provided attributes do 
not provide the information that is necessary to make an informed choice regarding priority 
setting for a vaccine programme? 
 
Reply: The reviewer makes an excellent point. Indeed, the fact that respondents might 
‘overestimate’ the importance of the side effects is in essence one of the subjects of this DCE. And 
indeed, we saw that there was a cluster of respondents who were more vaccine skeptical and gave 
higher weight to side effects. Evidence on the severity of side effects relative to the disease itself 
does vary, with most side effects typically less severe, however with  exceptions. Several vaccines 
can have (although rarely) severe side effects, often more severe than the disease the vaccine is 
preventing - eg. Guillian-Barre syndrome, anaphylaxis, intussusception etc. But the risk of these 
severe events is much less than the risk reduction in getting the disease after getting vaccinated. 
We opted for equal severity between prevented disease and induced side effects because this 
simplification reduced the need for respondents to simultaneously trade-off two disease severity 
profiles as well as the number of cases, likely improving the reliability of our results. To mitigate 
this issue that the reviewer correctly highlights, our questionnaire included a difference in the size 
of the direct impact and side effects—including an at least 10-fold lower disease burden linked to 
side-effects compared to the prevented disease burden. Indeed, turning the overall effect of side 
effects by total burden in this manner allowed us to more simply compare the weight of side 
effects to direct or herd effects (without having to convert these health effects to e.g. QALYs). We 
have further clarified this point in the revised manuscript.  
 
In the methods section:  
“The side effects of vaccination were presented in the DCE as identical to an episode of the disease 
that the vaccine usually prevents, in order to enable a direct comparison between the three effect 
types. Not doing so would have meant using a second health profile within one choice option (one 
for the disease and one for the side effects) and this would also have made the experiment 
substantially more difficult for the participants.”  
 
And in the study limitations:  
“There are several limitations. We did not include any mortality effects, nor did we include a 
difference in severity between the three vaccine effects, even though this would be more realistic 
(as side effects of vaccines are usually milder than the disease being prevented). We chose not to 
include these aspects because we wanted to avoid increasing the complexity of the survey and 
reducing the validity of the respondents’ answers by adding a second disease profile. Also, keeping 
the disease outcome constant over age groups and effects enabled trade-offs that were wholly 
reflective of the preference between age groups and effects instead of also reflecting additional 
considerations about disease severity.”  
 
 So, I would like to see a description of the qualitative process undertaken before the design of 
the DCE. For example: were qualitative interviews conducted with vaccination experts or 
people who are in favour or against vaccination? This would make it clear whether the 
selected attributes correspond with the missing information the public needs in order to make 
a valid judgement regarding priority setting for a vaccine programme. I could imagine that 
for example information about the long term effectiveness of a vaccine or protection duration 
could make a difference. For the attribute levels: the authors refer to expert opinion but again 
for me it is not clear what kind of experts were asked. The authors also refer to other DCE's 
although these were almost all disease-specific, referring to rotavirus or HPV vaccination. It is 
not clear how the levels from these choice experiments can easily translate to the ones used 
in this study.  
 
Reply: We agree that more info was needed on the process of selecting attributes and levels, see 
our response below. In fact, we think that constructing the list of 5 attributes for 4 different 
diseases was a merit of the design of this DCE. We used various inputs for this process and 
followed a trial and error approach towards finding the best possible form. We relied on our own 
judgment as researchers in this field and our assessment of the choice data that were needed to 
answer our research question, other DCEs in the literature but also on the feedback from 
colleagues and friends in earlier trial rounds and a pilot (N=69) in a later stage. Other DCEs were 
indeed context-specific but they gave us information on how various dimensions of health effect 
(e.g. mortality vs morbidity, competing dimensions of illness, side effects, etc.) were presented and 
traded-off, which personal attributes of vaccine recipients were included (age, gender, etc), etc. 
Some attributes with relevance in a wider assessment could be included indirectly, for example 
vaccine effectiveness could be modulated through the reduction in incidence of the disease. As 
with the nature of these questionnaires, a balance had to be struck between attribute inclusion 
and tractability for the respondent. We added the following in the methods section to provide 
more info on the process:  
 
“To develop the final attributes and levels of the vaccine programs included in the DCE, we 
followed a three stage iterative process. We performed a literature search of other vaccine-related 
DCEs to assess the choice context and which attributes and levels were considered in other studies. 
These attributes were disease incidence, case fatality risk, economic impact, duration of illness and 
duration of vaccine protection, severity of illness and severity of side effects, and various personal 
characteristics including age, gender and willingness/ability to get vaccinated. [40-44] From this 
list, we took the combination of attributes that was, in combination with the four disease profiles, 
best suited to answer our research question. We presented several versions to a convenience 
sample of lay persons, colleagues and collaborators at the market research company in a pilot 
questionnaire, which we revised in response to received comments. We re-iterated this process 
until we found the right form for the DCE from which, with a relatively simple set of in total five 
core attributes (Table 1), we could robustly calculate preference weights.”  
 
“After the design, we tested our survey among a pilot sample of the online panel (N=69) to confirm 
that respondents could fully understand and complete the survey. Based on the feedback from this 




 If I understand correctly, the cluster analysis revealed two group of respondents, one who 
attached no importance to the number of side-effects and another group who valued this 
highly. For cluster 1, it seems that the only predictor was no hesitancy on vaccination 
although the explained variance was low. However, I wonder  if the authors also performed 
an analysis to examine what was the predictor for the highly valued side effects in cluster 2. Is 
it possible that these are people who are very hesitant for vaccination?  
 
Reply: Thank you for this observation. Our previous phrasing was incomplete; the cluster 2 results 
were not mentioned whereas we in fact compared cluster 1 with cluster 2 in the analysis. We have 
changed this in the revised manuscript as follows: 
 
“We used a logistic regression to determine predictors of cluster membership. Cluster 1, which 
attached almost no importance to the number of side effects, was characterized by high values on 
the VHS, indicating little hesitancy (p<0.0001). On the other hand, cluster 2 who valued side effects 
more highly, was characterized by higher degrees of hesitancy on the VHS. However, the predictive 
power of this association for membership of the group was small (McFadden’s pseudo R2=0.6%), 




 the authors state that their study is the first one to quantify social value judgements in 
vaccine. Although this makes it difficult to compare their results with other studies, they 
indicate that one of their findings  is in line with theoretical expectations about cognitive 
heuristics like loss aversion, act-omission bias and hyperbolic discounting. My question is: why 
and could the authors explain this more in detail? What is for example the link between their 
findings and hyperbolic discounting or act-omission bias?  
 
Reply: Thank you for this comment. We have expanded the text as follows, and hope this is 
clearer. 
 
“The finding that individuals weighted one averted instance of a side effect equal to about three 
similarly severe natural infections in children can be explained with general theory on decision-
making. For instance, well-documented psychological phenomena such as ‘loss aversion’ (58) 
(overvaluing risks and losses over opportunities and gains), the ‘act-omission bias’ (59) (judging the 
effects of an act—becoming vaccinated—differently from identical effects resulting from an 
omission—becoming infected), or ‘hyperbolic discounting’ (60) (overvaluing the present—in which 
side effects occur—over the future—in which disease prevention will occur) suggest that people 
put an extraordinary weight on side effects when evaluating a vaccination strategy.” 
 
 Then the authors state that it is important to study which aspects of health policy choices 
matter most to the public. They mention that in particular public trust, goodwill and 
participation are key to success and that one has to be aware of the sensitivities surrounding 
vaccination. My question is: explain more to what extent your results might help to take away 
the sensitivities surrounding vaccination? The problem nowadays is that public trust or 
goodwill are often related to perceptions of risks (and not the actual risk of vaccination), a 
misconception about the severity of the disease like thinking that measles is an innocent virus 
that has no severe consequences. How are the selected five attributes direct effects of 
vaccination, targeted age of the vaccination programme, side effects related to vaccination, 
herd effects, the age group affected by the herd effects related to these issues?  
 
 
Reply: We have expanded the text on how our results could be used in practice. 
 
“Our findings provide empirical evidence on how to set vaccine priorities in line with public 
preferences. There is an important debate over the extent to which the public’s opinion should 
drive resource allocation in healthcare (see e.g. [67, 68]). But, many believe that the values of the 
public, who pays for healthcare, should at least somehow be acknowledged in the decision-making 
process. In the context of vaccination, where public support and participation is key to success, this 
concern becomes particularly crucial. Therefore, our results can be useful additions to vaccine 
appraisals. They can provide guidance in specific epidemiological cases where CEA does not 
provide the answers needed. For instance, our results would suggest that, despite their 
attractiveness in terms of cost-effectiveness, the public may not support a childhood influenza 
vaccination program that mainly benefits adults or elderly (), because preventing side effects in 
vaccinated children is preferred over preventing disease burden among adults and elderly. 
Furthermore, our study suggests that a childhood varicella-zoster vaccination program, in the case 
that it protects children against varicella disease at the expense of increased zoster in the elderly 
(the ‘exogenous boosting hypothesis’), might be justifiable. In contrast, previous analyses where 
QALY loss for children are weighted equally to those for the elderly find that the increased burden 
in the elderly offsets the QALY gains in children and determine the program not cost-effective (23 
77).   
Our results can also be directly incorporated into economic evaluations as sensitivity analyses to 
better align the underlying assumptions of CEA with the values of the population. Our estimated 
preference weights can be used in decision-analytic models as a parameter to weight QALYs or 
infections according to their ‘social value’. This would re-adjust the (equal) weight that QALYs 
receive in CEA according to how important people think that the age of the QALY-recipient is and 
whether the benefit was generated through direct protection, herd immunity or (avoiding) side-
effects. There is an increased interest in such ‘extended’, ‘distributive’ or ‘equity-weighted’ 
economic evaluation (see e.g. 7 36 70-75), but, to our knowledge, such studies do not exist for the 
evaluation of vaccines. Our estimates are developed particularly for this context, and provide an 
opportunity to do so.” 
 
Reviewer #2:  
 
Thank you for the opportunity to review your interesting research.  Overall this is a well written 
manuscript on an important topic. 
 
 Line 153 - did you pre-test your graphics to ensure comprehensibility and that it is measuring 
what you are expecting it to? 
 
Reply: Yes, we extensively tested the graphics and the wordings of the attributes and levels, first in 
groups of lay people and colleagues in our departments and among collaborators at the market 
research company and finally in a pilot of 69 online trial-participants. We have explained this 
piloting process more extensively in the revised manuscript. 
 
“To develop the final attributes and levels of the vaccine programs included in the DCE, we 
followed a three stage iterative process. We performed a literature search of other vaccine-related 
DCEs to assess the choice context and which attributes and levels were considered in other studies. 
These attributes were disease incidence, case fatality risk, economic impact, duration of illness and 
duration of vaccine protection, severity of illness and severity of side effects, and various personal 
characteristics including age, gender and willingness/ability to get vaccinated. [40-44] From this 
list, we took the combination of attributes that was, in combination with the four disease profiles, 
best suited to answer our research question. We presented several versions to a convenience 
sample of lay persons, colleagues and collaborators at the market research company in a pilot 
questionnaire, which we revised in response to received comments. We re-iterated this process 
until we found the right form for the DCE from which, with a relatively simple set of in total five 
core attributes (Table 1), we could robustly calculate preference weights..” 
 
“After the design, we tested our survey among a pilot sample of the online panel (N=69) to confirm 
that respondents could fully understand and complete the survey. Based on the feedback from this 
pilot sample we judged that the experiment was understandable and that no further changes were 
needed.” 
 
 Line 162 - what criteria did you use to choose your 45 choice sets? 
 
Reply: We have used the Bayesian D-optimal design criterion to generate the 45 choice sets of the 
DCE. This is also stated in the text at the end of Section 2.3, but for clarity, we added the following 
explanation:  
 
“The Bayesian D-optimal design then results in the smallest possible standard errors for the utility 
estimates at the given sample size”. 
 
 Line 183 - This is a rather generic sentence that does not give information about your pilot 
testing - were there any major or minor changes that resulted from your pilot testing? I am 
curious especially in how participants understood the attributes with a risk component - 
which as you know, can be interpreted quite differently between individuals depending on 
how you frame your attribute and levels.  Did participants suggest the graphics used for 
direct effects, side effects and indirect effects? 
 
Reply: We agree and have added more information in the revised manuscript on the process of 
pilot testing. We attempted to circumvent the problems related to risk by not including explicit 
risk-attributes, such as risk of disease, and instead include visual aids. As we did require some risk 
difference between attributes we chose to present the absolute number of prevented cases within 
the DCE, which is a combination of a risk of disease and a vaccine effectiveness. We helped the 
responders to differentiate between the numerical quantities by presenting graphical 
representations of the numbers in bars and blocks. We settled on the graphics within the iterative 
process of study design – a choice that highlights the order of magnitude difference between direct 
and side effects. Nevertheless, it might make a difference when we name the number of people 
without side effects rather than the complement with side effects (framing effects). However we 
think that our choice was defensible based on two considerations. First, we wanted to quantify the 
weight respondents placed on side effects and therefore we chose to frame side effects explicitly 
to ensure that people traded off vaccine-induced illness with natural infection, rather than neglect 
side effects and focus on the positive benefits. Second, our pilot testing showed that our framing 
made respondents reason in the way we anticipated: they clearly balanced good outcomes with 
negative ones. We agree that this point deserves more attention and we have therefore added the 
following to the Discussion section on study limitations in the revised manuscript. 
 
“We also chose to present the number of side effects rather than its complement: the number of 
vaccinated people without side effects. This framing may have played a role in the observed 
weight for side effects and the other framing would have likely generated lower estimates. We 
however wanted people to explicitly trade-off side effects with protective benefits.” 
 
 
 Line 188 - 50 pence for a 12 minute survey seems very low to me?  Is this the usual rate? 
 
Reply: This is indeed the usual rate that is applied by the market research company we recruited. 
 
 Line 232 - you mention 1546 started the questionnaire - how many survey links were sent 
out?  i.e. the true response rate would be the number potentially eligible as your 
denominator. 
 
Reply: In total there were 1950 surveys send out of which 1546 completed the full survey. We 
clarified this in the text as follows. 
 
“A total of 1546 respondents out of 1950 (79%) who were sent the questionnaire completed it, of 
which 47 (3%) indicated that the questions were too difficult or their answers invalid, leaving 1499 
questionnaires for analysis.” 
 
 Line 295 - you state your findings were robust across respondent characteristics - can you 
provide this information as supplemental information? 
 
Reply: Yes, we have now updated the manuscript accordingly and provide an extensive robustness 
check of the modelling results in Appendix D. 
 
Discussion - I know your choice sets are not specific to any disease but use general descriptors for 
severity. However, doesn't the specific type of disease actually impact on preferences? e.g. I suspect 
people would view a cancer vaccine (e.g. HPV) quite differently from a vaccine for influenza, all things 
being equal as measured by your 5 attributes.  There is something inherent in the disease itself that 
might be worth exploring for future studies.  But in your manuscript, might be worth a few sentences 
to discuss this possibility. 
 
Reply: Thank you for this suggestion. We have now raised this issue in the discussion with the 
study limitations.  
 
“Also, we used generic disease profiles based on a description in EQ-5D terms to minimize 
respondents making personal associations to the disease and vaccine (e.g. ‘flu’ or ‘whooping 
cough’), but this may also have increased the level of abstraction and reduced the level of personal 
involvement. A suggestion for further research is to repeat our study with named diseases and to 
test whether our finding that the disease profile did not matter to people’s preferences is 
confirmed.” 
 
 Line 368 - how specifically can other researchers use your preference weights in their models? 
can you give a concrete example? do you mean these weights can be used change WTP 
thresholds?  
 
Reply: We think that our results could be used experimentally to ‘weight’ QALYs in a decision 
model for vaccines according to public preferences over the weight of QALYs. CEA counts QALYs 
and assumes that all QALYs are equally valuable but our results (in line with other more general 
studies) suggest that this is not the case. Our preference weights could be used to provide an 
additional layer of information to these QALYs, about their ‘social value’. A QALY gained in a child 
would therefore weigh more than one gained in an adult. This is of course contentious but it 
provides, in our opinion, useful information for vaccine decision making where health interests 
between generations sometimes need to be traded off. We have added some more sentences on 
this in the new manuscript and suggested some examples.  
 
“For instance, our results would suggest that, despite their attractiveness in terms of cost-
effectiveness, the public may not support a childhood influenza vaccination program that mainly 
benefits adults or elderly [69], because preventing side effects in vaccinated children is preferred 
over preventing disease burden among adults and elderly. Furthermore, our study suggests that a 
childhood varicella-zoster vaccination program, in the case that it protects children against 
varicella disease at the expense of increased zoster in the elderly (the ‘exogenous boosting 
hypothesis’), might be justifiable. In contrast, previous analyses where QALY loss for children are 
weighted equally to those for the elderly find that the increased burden in the elderly offsets the 
QALY gains in children and determine the program not cost-effectiveOur findings can provide an 
empirical evidence base about how to set vaccine priorities in line with public preferences., 
because preventing side effects in vaccinated children is preferred highly over preventing disease 




“Our results can also be directly incorporated into economic evaluations (e.g. as sensitivity 
analyses), to better align the underlying assumptions of CEA with the values of the population. The 
preference weights we illustrated in Figure 3 can be used in decision-analytic models as a 
parameter to weight QALYs or infections according to their ‘social value’. This would re-adjust the 
(equal) weight that QALYs receive in CEA according to how important people think that the age of 
the QALY-recipient is and whether it was generated through direct protection, herd immunity or 
(avoiding) side-effects. There is an increased interest in such ‘extended’, ‘distributive’ or ‘equity-
weighted’ economic evaluation (see e.g. [7, 34, 71-76]), but, to our knowledge, such studies are 
inexistent for the evaluation of vaccines. Our estimates are developed particularly for this context, 
and provide an opportunity to do so.” 
 
 Table 1 - there is a big difference in the having children demographics between the study 
population and the UK population - any potential impact on your results?  
 
Reply: 42% is the percentage of UK families living with dependent children (<18 years old), which 
should be compared to 35% (both the 11% (0-4 yo) and 24% (5-20 yo) in the sample), so there is 
not a large difference in demographics between the sample and the UK population. Moreover, 
when we include parental status as a covariate in the model we see no significant effects of 
parental status (See supplementary material provided with this revision). 
 
 Table 1 - last row - 'participant affected by poor health' - seems like quite a significant 
proportion (27%) - how was poor health defined? - any potential impact on preferences? 
 
Reply: Poor health consisted of the following three answers: (1) neither I nor my close friends or 
family are affected by poor health, (2) I consider myself affected by poor health and (3) I am not 
affected but close friends or family are affected by poor health. The exact nature of "poor health" 
was left to the respondent rather than defined by us. However, this respondent characteristic had 
no impact on preferences, as indicated by a non-significant interaction effect with any of the 
attributes in the model. See supplementary material.  
 
 Table 2 - can you discuss the interpretation of your interaction results in your text in more 
detail?   
 
Reply: Thank you for this suggestion. We agree and we have added a new paragraph and a new 
figure to the revised manuscript. The interaction terms cannot easily be understood based on the 
estimates in the table but should be interpreted in terms of marginal utilities, consisting of the sum 
of the main effects of the two attributes involved and the interaction itself. We have added a new 
figure depicting the interaction between the two age groups and added the following to the results 
section: 
 
“Figure 4 illustrates the interaction between the age of the vaccinated group and the age of the 
herd immunity recipients (see Table 3). This interaction should be understood as the additional 
utility that is given to (or taken away from) a vaccination program, purely depending on the 
particular combination of age groups that are involved, regardless of the magnitude of direct, 
indirect or side effects that are being generated. It presents the attractiveness of particular 
intergenerational vaccination strategies. Whereas a CEA perspective would consider all possible 
age combinations equally attractive (as long as they lead to the same number of infections 
prevented), our sample had clear intergenerational preferences over vaccination strategies. Any 
age group was deemed acceptable to vaccinate when there were herd immunity benefits for 
newborns. To generate herd immunity for adults, infants were the most attractive age group. To 
generate it to protect the elderly >80, adults were deemed most appropriate. The least attractive 
intergenerational combination was vaccinating elderly >80 while generating herd immunity in 
adults 30-50 years. The most attractive age combination was vaccinating children while generating 
herd immunity in newborns.” 
 
 Figure 3 - I am a bit confused with your utility weights for side effects - aren't these supposed 
to be negative? Or is the label supposed to be "prevention of side effects?"? 
 
Reply: The QALYs for side effects are in principle negative but we presented them as a ‘weighting 
factor’ for QALYs that could be used in a decision model. In that case these QALYs are already 
being  ‘lost’ and it’s our weighing factor that multiplies this loss. We added the following 
clarifications:  
 
“Similarly, a vaccination strategy reduces its utility by causing side effects: reducing 34 side effects 
in children equals 100 prevented cases among the same age group.” 
 
And also:  
 
“The mean weight for side effects across all ages was -2.93, meaning that avoiding one vaccine-
induced infection was weighted equally to avoiding around three natural infections among 
children.” 
 
 Appendix B - any internal tests of validity incorporated into your experimental design? 
 
Reply: There were no internal tests incorporated in our experimental design, apart from our 
explicit question whether participants understood the questionnaire. The ultimate test of the 
internal validity of the design lies with the quality and reliability of responses that we observed. 
The preciseness of the estimates we obtained justifies the priors we used for the Bayesian design 
construction (see appendix C), which were based upon extensive deliberation amongst the 
authors. We have extensively piloted the different choice sets amongst colleagues until the choice 
sets were balanced in the level of complexity and as such manageable to make meaningful trade-
offs. Afterwards, only a small minority of respondents (N=47 or 3%) indicated that the choice sets 
were too difficult, and these respondents were excluded from the analysis. Moreover, the research 
company pledged to only include ‘serious’ responders based on previous experiences, time taken 




 Line 69 - please clarify your last phrase 'contestable perspective on them' - do you mean they 
only consider the healthcare perspective 
 
Reply: We agree that this statement was unclear and unnecessary and we have deleted this 
sentence from the introduction 
 
 A figure or table of all attributes with levels might be helpful. 
 
Reply: We have added a new table with all attributes and levels to the revised manuscript (Table 
1).  
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Quantifying the public’s view on social value judgments in 1 




Vaccination programs generate direct protection, herd protection and, occasionally, 6 
side effects, distributed over different age groups. This study elicits the general 7 
public’s view on how to balance these outcomes in funding decisions for vaccines. 8 
We performed an optimal design discrete choice experiment with partial profiles in a 9 
representative sample (N=1499) of the public in the United Kingdom. Using a panel 10 
mixed logit model, we quantified, for four different types of infectious disease, the 11 
importance of a person’s age during disease, how disease was prevented—via direct 12 
vaccine protection or herd protection—and whether the vaccine induced side effects. 13 
Our study shows clear patterns in how the public values vaccination programs. 14 
These diverge from the assumptions made in public health and cost-effectiveness 15 
models that inform decision-making. We found that side effects and infections in 16 
newborns and children were of primary importance to the perceived value of a 17 
vaccination program. Averting side effects was, in any age group, weighted three 18 
times as important as preventing an identical natural infection in a child whereas the 19 
latter was weighted six times as important as preventing the same infection in elderly 20 
aged 65-75 years. These findings were independent of the length or severity of the 21 
disease, and were robust across respondents’ backgrounds. We summarize these 22 




Priority-setting; age; side effects, herd protection, cost-effectiveness analysis, 27 
decision making; discrete choice experiment; preference weight, vaccination 28 
  29 
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1. Introduction 30 
Economic evaluation methods such as cost-effectiveness analysis (CEA) are 31 
common components in public funding decisions for vaccines [1, 2]. They feature in 32 
the standard evidence considered by e.g. the Advisory Committee on Immunization 33 
Practices in the US, the Joint Committee on Vaccination and Immunization in 34 
England, the World Health Organization and non-governmental organizations such 35 
as the Bill & Melinda Gates Foundation [3]. At the same time, it is widely 36 
acknowledged that these evaluation frameworks have important shortcomings and 37 
that they alone offer insufficient basis for making fair and efficient vaccine funding 38 
decisions [4-8]. There is a growing literature about the limits of CEA in assessing the 39 
value of vaccination [9-15].  40 
One important criticism is that CEA is limited in how it values the consequences of 41 
vaccination. Summary outcome measures [such as e.g. infections prevented or 42 
Quality-Adjusted Life Years (QALYs) gained] neglect the particular social context in 43 
which these outcomes occur. Nonetheless, such contextual features are important 44 
aspects to consider when evaluating a vaccination strategy. Vaccination induces 45 
disease protection in those who become vaccinated, but it also creates herd 46 
protection (or indirect effects in third parties because of reduced pathogen 47 
transmission [16]) and, occasionally, adverse clinical side effects. There are 48 
qualitative differences between these direct, herd and side effects. Creating herd 49 
protection can be of particular ethical value (e.g. to protect vulnerable groups who 50 
otherwise cannot protect themselves) and there is a profound psychological impact 51 
of vaccine-induced side effects. Moreover, the distribution of these three different 52 
effect types over different age groups is important. Side effects can be concentrated 53 
in one age group despite indirect protection from reduced transmission benefitting 54 
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either the wider population, or in some cases a different age group entirely [17]. 55 
Examples include protecting the elderly through childhood influenza vaccination or 56 
future generations through a polio eradication program. Such broader, distributive 57 
aspects of vaccination are important but they remain neglected in standard cost-58 
effectiveness or public health impact models.  59 
Several notable examples illustrate that this broader social context of health 60 
outcomes needs to be considered in vaccine decision-making [18]. For instance, 61 
vaccines against rotavirus (Rotashield®) and pertussis (whole cell pertussis vaccine) 62 
were withdrawn from many countries because of a perceived risk of side effects, 63 
even though from a medical perspective the benefit from vaccination largely 64 
outweighed any potential risk [19-21]. Also, despite persuasive economic and public 65 
health benefits of childhood influenza vaccination, few countries have actually 66 
implemented such a preventive strategy, due in large part to concerns about the 67 
social acceptability and equity of targeting vaccination at children to protect the wider 68 
population [22]. And, in many countries introduction of an effective varicella 69 
vaccination program has been delayed because of concerns about the possible 70 
‘exogenous boosting effect’ and its social repercussions, i.e. that reduced 71 
chickenpox transmission among children (due to varicella vaccination) might 72 
temporarily increase shingles incidence among older generations [23].  73 
Misjudging ethical norms and social sensitivities in vaccination policy by over-relying 74 
on CEA can have important implications. It may affect the perceived equity of a 75 
program, its support by the public and its long-term sustainability [13, 24-26] [27, 28]. 76 
It can invoke public backlash to the vaccine, leading to reduced uptake, increased 77 
vaccine hesitancy and reduced overall effectiveness of the program [29-31]. 78 
Therefore, an empirical evidence-base is needed about the public’s view on the key 79 
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value judgments that need to be made in vaccine funding decisions [9, 10, 12, 32, 80 
33]. Such evidence can complement formalized appraisals like CEA, stimulate 81 
deliberation and discussion on how to prioritize vaccines within a budget constraint 82 
and, moreover, it can be explored whether such evidence can become quantitatively 83 
integrated into formal decision frameworks in some sort of ‘extended’ or ‘weighted’ 84 
CEA [7, 34].  85 
The objective of this study is to address this challenge by analyzing how the 86 
population in the United Kingdom prioritizes vaccination programs and to investigate 87 
whether its values diverge from the assumptions that are implicitly underlying CEA. 88 
We use a discrete choice experiment (DCE) among a representative sample of the 89 
population in the United Kingdom (UK) to investigate, for four different types of 90 
infectious diseases, the role played by different age groups in a program’s overall 91 
evaluation and the extent to which it matters whether these age groups are affected 92 
by either direct, herd or side effects. We summarize these findings into a set of social 93 
preference weights for health outcomes (e.g. QALYs) that could be incorporated into 94 
economic evaluation or public health impact models.  95 
 96 
2. Methods  97 
DCEs are a widely used survey method to quantify individuals’ preferences [35, 36] 98 
(for a general review of applications, see [37]). Participants are presented with a 99 
series of choices, usually between two goods described by the same attributes but 100 
differing in their attribute levels. By observing respondents’ preferred choices, 101 
researchers can infer how the value of the competing options is determined by the 102 
attributes of the product. In our case, we observe how people prioritize between 103 
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vaccination programs based on the number of direct, herd and side effects 104 
generated by the program, and their distribution over different age groups. This 105 
allows us to estimate a utility function that describes how the public values 106 
vaccination programs, taking into account the different types of vaccine effect and 107 
their distribution. 108 
 109 
2.1 Choice context 110 
For all of their choices, respondents were randomly assigned one of four disease 111 
scenarios (see Appendix A). These were introduced before the start of the DCE. 112 
After five choice sets this disease was presented again to the respondent as a 113 
reminder. The four disease profiles were described as (1) severe—lasting nine days, 114 
(2) mild—lasting nine days, (3) severe—lasting 160 days, and (4) mild—lasting 160 115 
days. Influenza and pertussis were used as proxies for an acute severe and a longer 116 
lasting milder disease, respectively [38, 39]. To avoid participants’ preconceived 117 
ideas, the diseases were unnamed and only described to participants by means of 118 
severity using the generic descriptors of the dimensions of a standard instrument to 119 
measure health-related quality of life, the EuroQoL EQ-5D-3L, based on average 120 
reported values for both influenza and pertussis [38, 39]. To exclude considerations 121 
about age differences in remaining life expectancy, we explicitly told the participants 122 
that the diseases were not fatal.  123 
Before every choice set we told respondents the following: “the government has to 124 
choose between two vaccination programs that will each be used in 100 000 people. 125 
Considering your conviction about vaccination policy, which program do you think 126 
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the government should choose? Both options are equally costly, and identical in 127 
every way except for the following 5 differences.”  128 
 129 
2.2 Attributes and levels of vaccination programs 130 
To develop the final attributes and levels of the vaccine programs included in the 131 
DCE, we followed a three stage iterative process. We performed a literature search 132 
of other vaccine-related DCEs to assess the choice context and which attributes 133 
were typically considered. These attributes were disease incidence, case fatality risk, 134 
economic impact, duration of illness and duration of vaccine protection, severity of 135 
illness and severity of side effects, and various personal characteristics including 136 
age, gender and willingness/ability to get vaccinated. [40-44] From this list, we took 137 
the attributes that were, in combination with the four disease profiles, best suited to 138 
answer our research question. We presented several attribute combinations to a 139 
convenience sample of lay persons, colleagues and collaborators at the market 140 
research company in a pilot questionnaire, which we revised in response to received 141 
comments. We re-iterated this process until we found the right form for the DCE from 142 
which, with a relatively simple set of in total five core attributes (Table 1), we could 143 
robustly calculate preference weights.  144 
The first two attributes described the age group targeted for vaccination and 145 
magnitude of the direct effects among those vaccinated. The third attribute described 146 
the number of side effects occurring among those vaccinated. The side effects of 147 
vaccination were presented in the DCE as identical to an episode of the disease that 148 
the vaccine usually prevents, in order to enable a direct comparison between the 149 
three effect types. Not doing so would have meant using a second health profile 150 
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within one choice option (one for the disease and one for the side effects) and this 151 
would also have made the experiment substantially more difficult for the participants. 152 
The fourth and fifth attribute described the magnitude of the herd effects and the age 153 
group that received them. We decided to focus only on the morbidity aspects of 154 
illness because including mortality would require additional attributes for infected 155 
people in order to account for their differing life expectancy.  156 
For direct and herd protection we used 1000, 3000 or 5000 disease episodes 157 
prevented per 100,000 people vaccinated (an attack rate of 1-5% for a vaccine with 158 
a 100% efficacy), and for side effects 100, 300 or 500 disease episodes per 100,000 159 
people vaccinated (an attack rate of 0.1-0.5%). For direct protection and side effects, 160 
we considered the following three age groups: children aged between 3 months and 161 
3 years of age, adults aged between 30 and 50 years, and elderly aged between 65 162 
and 75 years. The age groups for herd protection represented groups that, in the 163 
case of the first two, are often difficult to vaccinate for immunological reasons: young 164 
children under 3 months, elderly above 80 years and unvaccinated adults between 165 
30 and 50 years.  166 
 167 
(insert Table 1) 168 
 169 
We depicted both the age group and quantity of cases avoided or caused by 170 
vaccination using simple graphics [45] (Figure 1). To explicitly investigate the 171 
assumption whether individuals ultimately look at the total impact of the program and 172 
to reduce the chance that respondents would adhere to a simple counting heuristic 173 
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without reflection, we presented the net number of disease cases averted for each 174 
strategy separately (the sum of direct and herd effects minus side effects).  175 
 176 
(insert Figure 1) 177 
 178 
2.3 Experimental design of the choice sets 179 
The design of a DCE refers to the number and composition of choice sets presented 180 
to each participant [46]. A set of 45 choice sets was selected out of the 58,806 181 
possible choice sets (see Appendix B for more info on the selection process) and 182 
distributed over three survey versions, so to limit the number of choice sets to be 183 
completed per respondent to 15. Therefore, each of the four disease profiles was 184 
represented in three different surveys (see Figure 2).  185 
 186 
(Insert Figure 2) 187 
 188 
The choice alternatives (i.e. profiles) themselves were ‘partial profiles’ [47, 54]. We 189 
varied and highlighted the levels of two to four of the five attributes in the choice sets 190 
and kept the remaining attribute(s) constant so that respondents did not have to 191 
simultaneously trade-off all five dimensions per choice (see Appendix B). Limiting 192 
the cognitive burden for respondents in a DCE increases the validity and reliability of 193 
their answers [48]. The design we generated was ‘D-optimal’ in a Bayesian 194 
framework fitting with a multinomial logit (MNL) model for the attributes’ main effects 195 
and six interactions between the two age attributes (direct and herd effects) and the 196 
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three magnitude attributes we deemed to be important a priori. We chose a Bayesian 197 
framework to integrate prior information on the respondents’ likely preferences [49] 198 
(see Appendix C). The Bayesian D-optimal design then results in the smallest 199 
possible standard errors for the utility estimates at the given sample size.   200 
 201 
2.4 Sample  202 
After the design, we tested our survey among a pilot sample of the online panel 203 
(N=69) to confirm that respondents could fully understand and complete the survey. 204 
Based on the feedback from this pilot sample we judged that the experiment was 205 
understandable and that no further changes were needed.  206 
From a consumer panel of 1 million UK members, 9613 random panelists were 207 
approached to participate in “a scientific study on resource allocation in healthcare”. 208 
Of these people, 4144 (43%) responded to the invitation. We recruited 1950 of them 209 
to fulfill predetermined quotas to provide a representative sample of the UK 210 
population in terms of gender, socio-economic strata (indicated by the occupation of 211 
the head of the household), age groups (20-29, 30-39, 40-49, 50-59, 60+ years), and 212 
urban vs. rural background.  213 
The DCE was conducted in November 2016. An email containing a link to the survey 214 
website was sent to participants and by clicking on the link respondents consented to 215 
participate, although they were free to stop or close the survey at any point. All 216 
respondents received a nominal incentive for study completion (£0.50 per 12-minute 217 
questionnaire). Before completing the DCE, respondents were asked to administer a 218 
survey tool to measure vaccine hesitancy [50], and were asked social-demographic 219 
questions and whether they have or had children. After the DCE, we asked about 220 
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their experience with severe diseases, their interpretation of the validity of the 221 
answers they provided and the overall difficulty of the DCE survey. 222 
We obtained informed consent from all respondents and ethical approval of the study 223 
from the Ethics Committee of the London School of Hygiene & Tropical Medicine 224 
(Ref 10335). We conducted the research in accordance with the Code of Conduct of 225 
the Market Research Society, which ensured that information is collected for 226 
research purposes only, is kept confidential, and respondent anonymity is 227 
guaranteed.  228 
 229 
2.5 Data analysis 230 
To quantify the weight of the five attributes and their levels in the utility attributed to a 231 
vaccination strategy, a panel mixed logit model (fitted by the Hierarchical Bayes 232 
method [51]) was used (see Table 3). The model involved seven main effects: four 233 
related to the two three-level categorical attributes describing the utility impact of a 234 
change in the targeted age group in direct and herd effects, and three related to the 235 
continuous attributes describing the impact of a change in the absolute number of 236 
disease cases via direct effects, side effects and herd effects. Besides these seven 237 
main effects the model also includes attribute interaction effects, indicating the 238 
additional change in utility because of a particular combination of attribute levels. We 239 
computed the overall significance of the attributes using likelihood ratio (LR) tests 240 
and measured the relative importance of the attributes by the logworth statistic (i.e. –241 
log10 (p-value of the LR-test)). The coefficients of the logit model were obtained by 242 
estimating the a priori model, i.e. the model with the utility function that seemed most 243 
appropriate when planning the DCE, and subsequently dropping the non-significant 244 
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model terms until we obtained a final model in which all effects had significant 245 
explanatory value at the 5% level. Models were fitted using the JMP 13 Pro Choice 246 
platform (based on 10,000 iterations, with the last 5000 used for estimation) 247 
assuming normally distributed parameters with no correlation between the attributes. 248 
Combining the main and interaction effects, this model allows calculating the 249 
additional utility of a vaccination program generated per additional health effect, i.e. 250 
per type of effect per age group (see the nine variations in Table 3). The 95% 251 
confidence intervals for the equity weights were estimated using the Delta method 252 
[52].  253 
 254 
We investigated heterogeneity in respondents’ preferences in two ways. First, by 255 
exploring the influence of the observed respondent characteristics on the average 256 
preferences and, second, by studying the unobserved preference heterogeneity by 257 
means of a hierarchical cluster analysis on the subject-specific estimates resulting 258 
from the Hierarchical Bayes approach. We favoured this two-stage modelling method 259 
as it performs equally well as one-stage modelling methods such as latent class 260 
modelling [53] while enabling us to parsimoniously derive the preference weights and 261 
their 95% confidence intervals.     262 
 263 
3. Results 264 
 265 
3.1 Response 266 
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A total of 1546 respondents out of 1950 (79%) who were sent the questionnaire 267 
completed it, of which 47 (3%) indicated that the questions were too difficult or their 268 
answers invalid, leaving 1499 questionnaires for analysis. Our final sample was 269 
sufficiently representative of the UK population in terms of gender, family size, socio-270 
economic status and education level (Table 2).  271 
 272 
(insert Table 2) 273 
 274 
3.2 Main effects and calculated weights 275 
Across all questionnaires, respondents made a total of 22,485 choices between 276 
vaccination programs. There was no significant effect observed of which of the three 277 
survey versions a participant received. Respondents did not systematically choose 278 
the program with the highest overall public health impact, i.e. the total of all 279 
prevented cases including direct, herd and side effects. In fact, only 99 respondents 280 
(6.6%) consistently opted for the most effective program in all of their choice sets. 281 
However, about half the respondents (738/1499) chose the most effective alternative 282 
in at least 70% of their choices, indicating that the total effect on the disease burden 283 
is important, but not the only factor in prioritizing vaccination programs.  284 
Table 3 presents an overview of the incremental utility of the main effects and 285 
interactions. The vaccination program that was least preferred (i.e. yielding minimum 286 
utility) was one that targeted the elderly (65-75y), generated the lowest number of 287 
prevented cases, the highest number of side effects, and the lowest number of cases 288 
prevented via herd protection in unvaccinated adults. The most preferred program 289 
(i.e. yielding maximum utility) was one that targeted children, generated the highest 290 
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number of prevented cases, the lowest number of side effects, and the highest 291 
number of cases prevented via herd protection in newborns.  292 
 293 
(insert Table 3) 294 
 295 
Using the same logit model, we then calculated preference weights for each effect 296 
type per age group. These weights act as a multiplicative factor to transform identical 297 
clinical symptoms into health effects with equal value in the public’s view. We 298 
compared the additional utility of a vaccination program that is generated through 299 
preventing one specific disease case relative to the utility gained through directly 300 
preventing a single disease case via vaccinating a child (Figure 3). These 301 
preference weights reveal important patterns. First, preventing side effects of 302 
vaccination was highly preferable to preventing natural infections, even though the 303 
symptoms were equal in length and severity. The mean weight for side effects 304 
across all ages was -2.93, meaning that avoiding one vaccine-induced infection was 305 
weighted equally to avoiding around three natural infections among children. This 306 
finding was consistent whether side effects occurred in children (-2.95 (95% CI: -307 
3.21; -2.69)), adults (-3.16 (95% CI: -3.51; -2.81)) or the elderly (-2.68 (95% CI: -308 
2.98; -2.37)). Second, respondents preferred vaccination programs that prevented 309 
disease among newborns and children compared with those for adults and the 310 
elderly, even though the prevented disease burden was similar. One episode 311 
prevented in a newborn via herd protection was considered about twice as valuable 312 
as directly protecting an adult via vaccination. Third, the extent to which respondents 313 
preferred protecting adults and the elderly depends on the type of benefit conferred 314 
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by the program. Direct effects were the preferred mode of protection for adults 315 
whereas herd effects were preferred for the elderly. Reducing disease burden by 316 
directly vaccinating adults (aged 30-50 years) was weighted equally to reducing 317 
disease burden in the elderly (aged 80+ years) via herd effects [0.75 (0.64; 0.85) 318 
compared to 0.67 (0.58; 0.76), respectively]. In contrast, reducing disease burden in 319 
adults (aged 30-50 years) by herd effects counted equally to reducing disease 320 
burden in elderly (aged 65-75 years) directly via vaccination (0.12 (0.03; 0.20) 321 
compared to 0.16 (0.06; 0.25), respectively).  322 
 323 
(insert Figure 3) 324 
 325 
From these results, we also calculated the number of infections needed to avert in 326 
order to obtain equal utility as that from protecting 100 children directly via 327 
vaccination (Table 4). Avoiding 100 infections in children via vaccination was 328 
considered equivalent to protecting 632 elderly (65-75 years) or 134 adults. In turn, 329 
these outcomes were equivalent to protecting 71 newborns, 865 adults or 150 330 
elderly (>80y) via herd protection. Similarly, a vaccination strategy reduces its utility 331 
by causing side effects. Avoiding 34 side effects in children generates the same 332 
utility as preventing 100 natural infections among the same age group.  333 
 334 




Figure 4 illustrates the significant interaction in our model between the age of the 337 
vaccinated group and the age of the herd protection recipients (see Table 3). This 338 
interaction must be understood as the additional utility that is given to (or taken away 339 
from) a vaccination program depending on the particular combination of age groups 340 
that are involved, regardless of the magnitude of direct, herd or side effects that are 341 
being generated. It presents the attractiveness of particular intergenerational 342 
vaccination strategies. Whereas a CEA perspective would consider all possible age 343 
combinations equally attractive (as long as they lead to the same number of 344 
infections prevented), our sample had clear intergenerational preferences over 345 
vaccination strategies. Any age group was deemed acceptable to vaccinate when 346 
there were herd protection benefits for newborns. To generate herd protection for 347 
adults, children were the most attractive age group. To generate it to protect the 348 
elderly >80, adults were deemed most appropriate. The least attractive 349 
intergenerational combination was vaccinating elderly 65-75 years while generating 350 
herd protection in adults 30-50 years. The most attractive age combination was 351 
vaccinating children while generating herd protection in newborns.  352 
 353 
(insert Figure 4) 354 
 355 
3.3 Preferences across disease types and respondents 356 
As shown in Appendix D, our results remained robust across all four different 357 
disease types: the equity weights were statistically equivalent, regardless of whether 358 
the condition was mild vs. severe or acute vs. chronic (indicated by a non-significant 359 
interaction effect in our model between the attributes and the disease type). Also, the 360 
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appendix illustrates that our findings also remained robust across most respondent 361 
characteristics: gender, age, occupation, level of education, urban-rural, socio-362 
economic background, experience with severe illness or parental status. Although 363 
individuals with a low degree of vaccine hesitancy (indicated by high values on the 364 
‘vaccine hesitancy scale’ (VHS) [50]) attributed less importance to side effects 365 
(p<0.0001), this effect was relatively small (a 10 unit increase in the VHS score (on a 366 
scale from 10 to 50) led to a 10% decrease in absolute magnitude of the utility for 367 
side effects (~0.03)).  368 
The hierarchical cluster analysis of the individual preferences (see methods) 369 
revealed two distinct groups of respondents: one group (N=564, Cluster 1) who 370 
attached almost no importance to the number of side effects (with a mean weight of -371 
0.91 for side effects) and a larger group (N=935, Cluster 2) who valued this attribute 372 
fairly highly (with a mean weight of -4.40) (Table 3). This clustering explains the 373 
relatively high variation across respondents for the weight estimate for side effects 374 
(the standard deviation to mean absolute value ratio of 0.043 for side effects is 375 
almost twice the ratio for direct and herd effects). We used a logistic regression to 376 
determine predictors of cluster membership. Cluster 1, who attached almost no 377 
importance to the number of side effects, was characterized by high values on the 378 
VHS, indicating little hesitancy (p<0.0001). On the other hand, cluster 2, who valued 379 
side effects more highly, was characterized by higher degrees of hesitancy on the 380 
VHS. However, the predictive power of this association for membership of the group 381 
was small (McFadden’s pseudo R2=0.6%), implying that there is much unexplained 382 




  385 
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4. Discussion 386 
In this study, we used a discrete choice experiment to analyse and quantify how the 387 
public values the outcomes of vaccination programs. We observed several general 388 
preference patterns, which were robust across different lengths and severities of 389 
disease and respondent characteristics (socio-economic background, age, education 390 
and parenthood). We observed that most respondents did not make choices purely 391 
based on how to minimize the number of infections. In particular, individuals, on 392 
average, weighted one averted instance of a side effect equal to about three similarly 393 
severe natural infections in children and weighted one averted health outcome in 394 
children up to six times more than preventing similarly severe health outcomes in the 395 
elderly. Interestingly, our study has disentangled this latter phenomenon from the 396 
type of effect as we observed a different weight given to protecting older people 397 
depending on whether the benefits were directly vs. indirectly received. Our results 398 
support a duty of care principle to provide herd protection for the elderly and an 399 
aversion to protecting adults who are better able to protect themselves. The weight 400 
given to side effects when evaluating a vaccination program was divisive, splitting 401 
our sample into two clusters.  402 
Our study, as far as we are aware, is the first of its kind to quantify the important 403 
social value judgements that need to be made in vaccine funding decisions. 404 
Although this limits comparability, our findings are in line with what can be learned 405 
from other study domains. The finding that individuals weighted one averted instance 406 
of a side effect equal to about three similarly severe natural infections in children can 407 
be explained with general theory on decision-making. For instance, well-documented 408 
psychological phenomena such as ‘loss aversion’ [55] (overvaluing risks and losses 409 
over opportunities and gains), the ‘act-omission bias’ [56] [judging the effects of an 410 
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act (becoming vaccinated) differently from identical effects resulting from an 411 
omission (becoming infected)], or ‘hyperbolic discounting’ [57] [overvaluing the 412 
present (in which side effects occur) over the future (in which disease prevention will 413 
occur)] suggest that people put an extraordinary weight on side effects when 414 
evaluating a vaccination strategy. Moreover, also empirical studies that have 415 
investigated people’s (stated) choices about whether or not they would personally 416 
become vaccinated with a particular vaccine (e.g. [43, 58]) generated findings that 417 
highlight the extraordinary weight of side effects. The preference given to health 418 
benefits in younger people (newborns and children), up to six-fold, is also in line with 419 
related studies on ‘ageism’ in other contexts of healthcare priority-setting (reviewed 420 
in [59] and discussed elsewhere, e.g. [60, 61]).  421 
It is important to study which aspects of health policy choices matter most to the 422 
public. This is especially true in vaccination where public trust, goodwill and 423 
participation are sensitive and key to success [62]. There is a growing concern that 424 
public and political trust in scientific evidence is eroding, particularly in the context of 425 
vaccination [63-65]. By being aware of the sensitivities around vaccination, decision 426 
makers can understand and address some of the root causes of vaccine hesitancy, 427 
adapt to concerns of the population and improve responses in communication 428 
strategies.[66] Our findings provide empirical evidence on how to set vaccine 429 
priorities in line with public preferences. There is an important debate over the extent 430 
to which the public’s opinion should drive resource allocation in healthcare (see e.g. 431 
[67, 68]). But, many believe that the values of the public, who pays for healthcare, 432 
should at least somehow be acknowledged in the decision-making process. In the 433 
context of vaccination, where public support and participation is key to success, this 434 
concern becomes particularly crucial. Therefore, our results can be useful additions 435 
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to vaccine appraisals. They can provide guidance in specific epidemiological cases 436 
where CEA does not provide the answers needed. For instance, our results would 437 
suggest that, despite their attractiveness in terms of cost-effectiveness, the public 438 
may not support a childhood influenza vaccination program that mainly benefits 439 
adults or elderly [69], because preventing side effects in vaccinated children is 440 
preferred over preventing disease burden among adults and elderly. Furthermore, 441 
our study suggests that a childhood varicella-zoster vaccination program, in the case 442 
that it protects children against varicella disease at the expense of increased zoster 443 
in the elderly (the ‘exogenous boosting hypothesis’), might be justifiable. In contrast, 444 
previous analyses where QALY losses for children are weighted equally to those for 445 
the elderly find that the increased burden in the elderly offsets the QALY gains in 446 
children and determine the program not cost-effective [23, 70].  447 
Our results can also be directly incorporated into economic evaluations as sensitivity 448 
analyses to better align the underlying assumptions of CEA with the values of the 449 
population. Our estimated preference weights can be used in decision-analytic 450 
models as a parameter to weight QALYs or infections according to their ‘social 451 
value’. This would re-adjust the (equal) weight that QALYs receive in CEA according 452 
to how important people think that the age of the QALY-recipient is and whether the 453 
benefit was generated through direct protection, herd immunity or (avoiding) side 454 
effects. There is an increased interest in such ‘extended’, ‘distributive’ or ‘equity-455 
weighted’ economic evaluation (see e.g. [7, 34, 71-76]), but, to our knowledge, such 456 
studies do not exist for the evaluation of vaccines. Our estimates are developed 457 
particularly for this context, and provide an opportunity to do so.  458 
There are several limitations. We did not include any mortality effects, nor did we 459 
include a difference in severity between the three vaccine effects, even though this 460 
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would be more realistic (as side effects of vaccines are usually milder than the 461 
disease being prevented). We chose not to include these aspects because we 462 
wanted to avoid increasing the complexity of the survey and reducing the validity of 463 
the respondents’ answers by adding a second disease profile. Also, keeping the 464 
disease outcome constant over age groups and effects enabled trade-offs that were 465 
wholly reflective of the preference between age groups and effects instead of also 466 
reflecting additional considerations about disease severity. We also chose to present 467 
the number of side effects rather than its complement the number of vaccinated 468 
people without side effects. This framing may have played a role in the observed 469 
weight for side effects. The alternative framing would probably have drawn less 470 
attention to side effects and might have generated smaller weights. We however 471 
wanted people to make explicit trade-offs between side effects with protective 472 
benefits and chose for the more direct framing. Using the alternative is a suggestion 473 
for further research.  Also, we used generic disease profiles based on a description 474 
in EQ-5D terms to minimize respondents making personal associations to the 475 
disease and vaccine when we would have named the diseases (e.g. ‘flu’ or 476 
‘whooping cough’), but this may also have increased the level of abstraction and 477 
reduced the level of personal involvement. A suggestion for further research is to 478 
repeat our study with named diseases and to test whether our finding that the 479 
disease profile did not matter to people’s preferences is confirmed. Another limitation 480 
is that, while our sample was broadly representative of the UK population, it was 481 
recruited from an online panel where membership may be associated with 482 
unobserved characteristics (e.g. interest in technology).  483 
In conclusion, our study demonstrates clear and robust preference patterns in how 484 
people value the impact of vaccination programs. A large majority of respondents 485 
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had a strong preference to minimize side effects and to prevent disease among 486 
newborns and children. Our observations provide quantitative evidence about public 487 
preferences around important and sensitive but neglected trade-offs in vaccine policy 488 
decision-making, and can hopefully inspire further research and discussion.   489 
 490 
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Table 1. Attributes and levels used in the DCE 653 
Attribute Level 
Age of vaccinated group (N=100 000) Children (3 months -  3 years) 
Adults (30-50 years) 
Elderly (65-75 years) 
Disease episodes prevented in 




Number of vaccine-induced side-effects 100 cases 
300 cases 
500 cases 





Age of people receiving herd protection Newborns (<3 months) 
Adults (30-50 years) 
Elderly (>80 years) 
 654 




Table 2: Respondent characteristics. 657 
 Sample UK population* 
Total recruited 1546   
Excluded for analysis 47  
Included in the analysis 1499 (100%)  
Gender   
Male 703 (47%) 49% 
Female 796 (53%) 51% 
Age (years)   
20-29 296 (20%) 13% 
30-39 285 (19%) 13% 
40-49 288 (19%) 14% 
50-59 308 (21%) 13% 
60 and over 322 (21%) 23% 
Living in a city with more than 10,000 
inhabitants  
1011 (67%) 83% 
Social grades based on the profession of the 
highest paid household member  
  
A (upper middle class) 85 (6%) 4% 
B (middle class) 297 (20%) 23% 
C1 (lower middle class) 385 (26%) 27% 
C2 (skilled working class) 330 (22%) 21% 
D (working class) 72 (5%) 16% 
E  (non-working) 330 (22%) 9% 
Education level   
No qualifications 48 (3%) 15% 
Secondary education  322 (21%) 14.2% 
Post-secondary education 288 (19%) 14.5% 
Vocational qualification 254 (17%) 20.3% 
Undergraduate degree, Post-graduate 
degree & Doctorate  




*UK population data 2016: Office for National Statistics https://www.gov.uk/government/publications  659 















Not sure 2 (0.1%) / 
Having children   
No children 585 (39%) 42% 
Children aged 0-4 years 168 (11%) 42%** 
Children aged 5-20 years 358 (24%) / 
Children aged over 20 years 388 (26%) 15% 
Exposure to poor health    
Participant affected by poor health 407 (27%)  
Close friends or family of the participant 
affected by poor health 
470 (31%)  
Neither participant nor close friends nor 
family affected by poor health 




Table 3. Attributes that affected respondent choices, based on panel mixed logit model estimates (means and standard 676 
deviations) with p-values from likelihood ratio (LR) tests for significant attribute effects.  677 
Model term Posterior mean Posterior std dev Subject std dev P-value 
Cases prevented in unvaccinated by herd effects  
(per 1000 cases) 0.715 0.018 0.101 <0.0001 
Cases prevented in vaccinated by direct effects (per 1000 
cases) 0.619 0.018 0.100 <0.0001 
Cases of side effects in vaccinated (per 100 cases) -0.285 0.012 0.110 <0.0001 
Age of unvaccinated  
 
 
[Newborns <3m] 0.614 0.048 0.090 <0.0001 
[Adults 30-50y] -0.597 0.043 0.105   
[Elderly >80y] -0.017  NA  NA   
Age of unvaccinated*Cases 
prevented in vaccinated by 
direct effects 
[Newborns <3m] -0.043 0.009 0.054 <0.0001 
[Adults 30-50y] 0.071 0.009 0.041   
[Elderly >80y] -0.028  NA  NA   
Age of vaccinated  
 
 
[Children 3m-3y] 0.305 0.040 0.063 <0.0001 
[Adults 30-50y] 0.142 0.048 0.062   
[Elderly 65-75y] -0.446  NA  NA   





[Newborns <3m]* [Children 3m-
3y] -0.131 0.036 0.053 <0.0001 
[Newborns <3m]* [Adults 30-
50y] -0.210 0.041 0.065   
[Newborns <3m]* [Elderly 65- 0.341  NA  NA   
30 
 
Note: Mean estimates corresponding to the last level of an attribute, either as a main effect or involved in an interaction, are italicized and calculated as minus 678 






[Adults 30-50y]* [Children 3m-
3y] 0.250 0.052 0.044   
[Adults 30-50y]* [Adults 30-
50y] -0.079 0.049 0.045   
[Adults 30-50y]* [Elderly 65-
75y] -0.171  NA  NA   
[Elderly >80y]* [Children 3m-
3y] -0.119  NA  NA   
[Elderly >80y]* [Adults 30-50y] 0.289  NA  NA   
[Elderly >80y]* [Elderly 65-75y] -0.170  NA  NA   
Age of vaccinated*Cases of 
side effects in vaccinated 
[Children 3m-3y] -0.032 0.008 0.040 <0.0001 
[Adults 30-50y] -0.037 0.009 0.044   
[Elderly 65-75y] 0.069  NA  NA   
Age of unvaccinated*Cases 
prevented in unvaccinated by 
herd effects 
[Newborns <3m] 0.052 0.009 0.048 <0.0001 
[Adults 30-50y] -0.005 0.008 0.043   
[Elderly >80y] -0.047  NA  NA   
Age of vaccinated*Cases 
prevented in vaccinated by 
direct effects 
[Children 3m-3y] 0.051 0.010 0.044 <0.0001 
[Adults 30-50y] -0.032 0.009 0.037   
[Elderly 65-75y] -0.019  NA  NA   
31 
 
Table 4. Number of infections to prevent to gain equal utility, with 95% 680 
confidence intervals.  681 
Age group of 
vaccine effect 
Direct effects Herd effects Side effects 
Newborns  
(<3 months) 




(3 months – 3 years) 
100  
[index] 
NA -34  
[-37; -31] 
   Cluster 1: -221 [-340; -102]  








 [-35; -28] 
   Cluster 1: -72 [-93; -51] 





NA -37  
[-42; -33] 
   Cluster 1: -113 [-163; -64] 
   Cluster 2: -25 [-27; -22]  
Elderly  
(>80 years) 
NA 150  
[130; 169] 
NA 
Note: Cluster 1 and 2 have 564 and 935 respondents, respectively; NA refers to combinations of 682 
attribute levels not included in the choice profiles. 683 
  684 
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Figure 1. Example of a choice set. 685 
 686 
Figure 2. Schematic representation of the different arms of the questionnaire. 687 
For each disease stratum, there was also an equal sampling over the socio-688 
economic groups (25% A+B; 25% C1; 25% C2; 25% E+D). 689 
 690 
Figure 3. Utility weights representing public preferences for identical health 691 
outcomes with different attributes, with 95% confidence intervals. 692 
 693 
Figure 4. Intergenerational preferences: interaction effects between the age 694 
group vaccinated and the age group receiving herd protection effects. 695 
Marginal utility values consist of main effects of the attributes involved and 696 





Quantifying the public’s view on social value judgments in 1 




Vaccination programs generate direct protection, herd protection and, occasionally, 6 
side effects, distributed over different age groups. This study elicits the general 7 
public’s view on how to balance these outcomes in funding decisions for vaccines. 8 
We performed an optimal design discrete choice experiment with partial profiles in a 9 
representative sample (N=1499) of the public in the United Kingdom. Using a panel 10 
mixed logit model, we quantified, for four different types of infectious disease, the 11 
importance of a person’s age during disease, how disease was prevented—via direct 12 
vaccine protection or herd protection—and whether the vaccine induced side effects. 13 
Our study shows clear patterns in how the public values vaccination programs. 14 
These diverge from the assumptions made in public health and cost-effectiveness 15 
models that inform decision-making. We found that side effects and infections in 16 
newborns and children were of primary importance to the perceived value of a 17 
vaccination program. Averting side effects was, in any age group, weighted three 18 
times as important as preventing an identical natural infection in a child whereas the 19 
latter was weighted six times as important as preventing the same infection in elderly 20 
aged 65-75 years. These findings were independent of the length or severity of the 21 
disease, and were robust across respondents’ backgrounds. We summarize these 22 
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1. Introduction 30 
Economic evaluation methods such as cost-effectiveness analysis (CEA) are 31 
common components in public funding decisions for vaccines [1, 2]. They feature in 32 
the standard evidence considered by e.g. the Advisory Committee on Immunization 33 
Practices in the US, the Joint Committee on Vaccination and Immunization in 34 
England, the World Health Organization and non-governmental organizations such 35 
as the Bill & Melinda Gates Foundation [3]. At the same time, it is widely 36 
acknowledged that these evaluation frameworks have important shortcomings and 37 
that they alone offer insufficient basis for making fair and efficient vaccine funding 38 
decisions [4-8]. There is a growing literature about the limits of CEA in assessing the 39 
value of vaccination [9-15].  40 
One important criticism is that CEA is limited in how it values the consequences of 41 
vaccination. Summary outcome measures [such as e.g. infections prevented or 42 
Quality-Adjusted Life Years (QALYs) gained] neglect the particular social context in 43 
which these outcomes occur. Nonetheless, such contextual features are important 44 
aspects to consider when evaluating a vaccination strategy. Vaccination induces 45 
disease protection in those who become vaccinated, but it also creates herd 46 
protection (or indirect effects in third parties because of reduced pathogen 47 
transmission [16]) and, occasionally, adverse clinical side effects. There are 48 
qualitative differences between these direct, herd and side effects. Creating herd 49 
protection can be of particular ethical value (e.g. to protect vulnerable groups who 50 
otherwise cannot protect themselves) and there is a profound psychological impact 51 
of vaccine-induced side effects. Moreover, the distribution of these three different 52 
effect types over different age groups is important. Side effects can be concentrated 53 
in one age group despite indirect protection from reduced transmission benefitting 54 
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either the wider population, or in some cases a different age group entirely [17]. 55 
Examples include protecting the elderly through childhood influenza vaccination or 56 
future generations through a polio eradication program. Such broader, distributive 57 
aspects of vaccination are important but they remain neglected in standard cost-58 
effectiveness or public health impact models.  59 
Several notable examples illustrate that this broader social context of health 60 
outcomes needs to be considered in vaccine decision-making [18]. For instance, 61 
vaccines against rotavirus (Rotashield®) and pertussis (whole cell pertussis vaccine) 62 
were withdrawn from many countries because of a perceived risk of side effects, 63 
even though from a medical perspective the benefit from vaccination largely 64 
outweighed any potential risk [19-21]. Also, despite persuasive economic and public 65 
health benefits of childhood influenza vaccination, few countries have actually 66 
implemented such a preventive strategy, due in large part to concerns about the 67 
social acceptability and equity of targeting vaccination at children to protect the wider 68 
population [22]. And, in many countries introduction of an effective varicella 69 
vaccination program has been delayed because of concerns about the possible 70 
‘exogenous boosting effect’ and its social repercussions, i.e. that reduced 71 
chickenpox transmission among children (due to varicella vaccination) might 72 
temporarily increase shingles incidence among older generations [23].  73 
Misjudging ethical norms and social sensitivities in vaccination policy by over-relying 74 
on CEA can have important implications. It may affect the perceived equity of a 75 
program, its support by the public and its long-term sustainability [13, 24-26] [27, 28]. 76 
It can invoke public backlash to the vaccine, leading to reduced uptake, increased 77 
vaccine hesitancy and reduced overall effectiveness of the program [29-31]. 78 
Therefore, an empirical evidence-base is needed about the public’s view on the key 79 
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value judgments that need to be made in vaccine funding decisions [9, 10, 12, 32, 80 
33]. Such evidence can complement formalized appraisals like CEA, stimulate 81 
deliberation and discussion on how to prioritize vaccines within a budget constraint 82 
and, moreover, it can be explored whether such evidence can become quantitatively 83 
integrated into formal decision frameworks in some sort of ‘extended’ or ‘weighted’ 84 
CEA [7, 34].  85 
The objective of this study is to address this challenge by analyzing how the 86 
population in the United Kingdom prioritizes vaccination programs and to investigate 87 
whether its values diverge from the assumptions that are implicitly underlying CEA. 88 
We use a discrete choice experiment (DCE) among a representative sample of the 89 
population in the United Kingdom (UK) to investigate, for four different types of 90 
infectious diseases, the role played by different age groups in a program’s overall 91 
evaluation and the extent to which it matters whether these age groups are affected 92 
by either direct, herd or side effects. We summarize these findings into a set of social 93 
preference weights for health outcomes (e.g. QALYs) that could be incorporated into 94 
economic evaluation or public health impact models.  95 
 96 
2. Methods  97 
DCEs are a widely used survey method to quantify individuals’ preferences [35, 36] 98 
(for a general review of applications, see [37]). Participants are presented with a 99 
series of choices, usually between two goods described by the same attributes but 100 
differing in their attribute levels. By observing respondents’ preferred choices, 101 
researchers can infer how the value of the competing options is determined by the 102 
attributes of the product. In our case, we observe how people prioritize between 103 
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vaccination programs based on the number of direct, herd and side effects 104 
generated by the program, and their distribution over different age groups. This 105 
allows us to estimate a utility function that describes how the public values 106 
vaccination programs, taking into account the different types of vaccine effect and 107 
their distribution. 108 
 109 
2.1 Choice context 110 
For all of their choices, respondents were randomly assigned one of four disease 111 
scenarios (see Appendix A). These were introduced before the start of the DCE. 112 
After five choice sets this disease was presented again to the respondent as a 113 
reminder. The four disease profiles were described as (1) severe—lasting nine days, 114 
(2) mild—lasting nine days, (3) severe—lasting 160 days, and (4) mild—lasting 160 115 
days. Influenza and pertussis were used as proxies for an acute severe and a longer 116 
lasting milder disease, respectively [38, 39]. To avoid participants’ preconceived 117 
ideas, the diseases were unnamed and only described to participants by means of 118 
severity using the generic descriptors of the dimensions of a standard instrument to 119 
measure health-related quality of life, the EuroQoL EQ-5D-3L, based on average 120 
reported values for both influenza and pertussis [38, 39]. To exclude considerations 121 
about age differences in remaining life expectancy, we explicitly told the participants 122 
that the diseases were not fatal.  123 
Before every choice set we told respondents the following: “the government has to 124 
choose between two vaccination programs that will each be used in 100 000 people. 125 
Considering your conviction about vaccination policy, which program do you think 126 
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the government should choose? Both options are equally costly, and identical in 127 
every way except for the following 5 differences.”  128 
 129 
2.2 Attributes and levels of vaccination programs 130 
To develop the final attributes and levels of the vaccine programs included in the 131 
DCE, we followed a three stage iterative process. We performed a literature search 132 
of other vaccine-related DCEs to assess the choice context and which attributes 133 
were typically considered. These attributes were disease incidence, case fatality risk, 134 
economic impact, duration of illness and duration of vaccine protection, severity of 135 
illness and severity of side effects, and various personal characteristics including 136 
age, gender and willingness/ability to get vaccinated. [40-44] From this list, we took 137 
the attributes that were, in combination with the four disease profiles, best suited to 138 
answer our research question. We presented several attribute combinations to a 139 
convenience sample of lay persons, colleagues and collaborators at the market 140 
research company in a pilot questionnaire, which we revised in response to received 141 
comments. We re-iterated this process until we found the right form for the DCE from 142 
which, with a relatively simple set of in total five core attributes (Table 1), we could 143 
robustly calculate preference weights.  144 
The first two attributes described the age group targeted for vaccination and 145 
magnitude of the direct effects among those vaccinated. The third attribute described 146 
the number of side effects occurring among those vaccinated. The side effects of 147 
vaccination were presented in the DCE as identical to an episode of the disease that 148 
the vaccine usually prevents, in order to enable a direct comparison between the 149 
three effect types. Not doing so would have meant using a second health profile 150 
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within one choice option (one for the disease and one for the side effects) and this 151 
would also have made the experiment substantially more difficult for the participants. 152 
The fourth and fifth attribute described the magnitude of the herd effects and the age 153 
group that received them. We decided to focus only on the morbidity aspects of 154 
illness because including mortality would require additional attributes for infected 155 
people in order to account for their differing life expectancy.  156 
For direct and herd protection we used 1000, 3000 or 5000 disease episodes 157 
prevented per 100,000 people vaccinated (an attack rate of 1-5% for a vaccine with 158 
a 100% efficacy), and for side effects 100, 300 or 500 disease episodes per 100,000 159 
people vaccinated (an attack rate of 0.1-0.5%). For direct protection and side effects, 160 
we considered the following three age groups: children aged between 3 months and 161 
3 years of age, adults aged between 30 and 50 years, and elderly aged between 65 162 
and 75 years. The age groups for herd protection represented groups that, in the 163 
case of the first two, are often difficult to vaccinate for immunological reasons: young 164 
children under 3 months, elderly above 80 years and unvaccinated adults between 165 
30 and 50 years.  166 
 167 
(insert Table 1) 168 
 169 
We depicted both the age group and quantity of cases avoided or caused by 170 
vaccination using simple graphics [45] (Figure 1). To explicitly investigate the 171 
assumption whether individuals ultimately look at the total impact of the program and 172 
to reduce the chance that respondents would adhere to a simple counting heuristic 173 
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without reflection, we presented the net number of disease cases averted for each 174 
strategy separately (the sum of direct and herd effects minus side effects).  175 
 176 
(insert Figure 1) 177 
 178 
2.3 Experimental design of the choice sets 179 
The design of a DCE refers to the number and composition of choice sets presented 180 
to each participant [46]. A set of 45 choice sets was selected out of the 58,806 181 
possible choice sets (see Appendix B for more info on the selection process) and 182 
distributed over three survey versions, so to limit the number of choice sets to be 183 
completed per respondent to 15. Therefore, each of the four disease profiles was 184 
represented in three different surveys (see Figure 2).  185 
 186 
(Insert Figure 2) 187 
 188 
The choice alternatives (i.e. profiles) themselves were ‘partial profiles’ [47, 54]. We 189 
varied and highlighted the levels of two to four of the five attributes in the choice sets 190 
and kept the remaining attribute(s) constant so that respondents did not have to 191 
simultaneously trade-off all five dimensions per choice (see Appendix B). Limiting 192 
the cognitive burden for respondents in a DCE increases the validity and reliability of 193 
their answers [48]. The design we generated was ‘D-optimal’ in a Bayesian 194 
framework fitting with a multinomial logit (MNL) model for the attributes’ main effects 195 
and six interactions between the two age attributes (direct and herd effects) and the 196 
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three magnitude attributes we deemed to be important a priori. We chose a Bayesian 197 
framework to integrate prior information on the respondents’ likely preferences [49] 198 
(see Appendix C). The Bayesian D-optimal design then results in the smallest 199 
possible standard errors for the utility estimates at the given sample size.   200 
 201 
2.4 Sample  202 
After the design, we tested our survey among a pilot sample of the online panel 203 
(N=69) to confirm that respondents could fully understand and complete the survey. 204 
Based on the feedback from this pilot sample we judged that the experiment was 205 
understandable and that no further changes were needed.  206 
From a consumer panel of 1 million UK members, 9613 random panelists were 207 
approached to participate in “a scientific study on resource allocation in healthcare”. 208 
Of these people, 4144 (43%) responded to the invitation. We recruited 1950 of them 209 
to fulfill predetermined quotas to provide a representative sample of the UK 210 
population in terms of gender, socio-economic strata (indicated by the occupation of 211 
the head of the household), age groups (20-29, 30-39, 40-49, 50-59, 60+ years), and 212 
urban vs. rural background.  213 
The DCE was conducted in November 2016. An email containing a link to the survey 214 
website was sent to participants and by clicking on the link respondents consented to 215 
participate, although they were free to stop or close the survey at any point. All 216 
respondents received a nominal incentive for study completion (£0.50 per 12-minute 217 
questionnaire). Before completing the DCE, respondents were asked to administer a 218 
survey tool to measure vaccine hesitancy [50], and were asked social-demographic 219 
questions and whether they have or had children. After the DCE, we asked about 220 
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their experience with severe diseases, their interpretation of the validity of the 221 
answers they provided and the overall difficulty of the DCE survey. 222 
We obtained informed consent from all respondents and ethical approval of the study 223 
from the Ethics Committee of the London School of Hygiene & Tropical Medicine 224 
(Ref 10335). We conducted the research in accordance with the Code of Conduct of 225 
the Market Research Society, which ensured that information is collected for 226 
research purposes only, is kept confidential, and respondent anonymity is 227 
guaranteed.  228 
 229 
2.5 Data analysis 230 
To quantify the weight of the five attributes and their levels in the utility attributed to a 231 
vaccination strategy, a panel mixed logit model (fitted by the Hierarchical Bayes 232 
method [51]) was used (see Table 3). The model involved seven main effects: four 233 
related to the two three-level categorical attributes describing the utility impact of a 234 
change in the targeted age group in direct and herd effects, and three related to the 235 
continuous attributes describing the impact of a change in the absolute number of 236 
disease cases via direct effects, side effects and herd effects. Besides these seven 237 
main effects the model also includes attribute interaction effects, indicating the 238 
additional change in utility because of a particular combination of attribute levels. We 239 
computed the overall significance of the attributes using likelihood ratio (LR) tests 240 
and measured the relative importance of the attributes by the logworth statistic (i.e. –241 
log10 (p-value of the LR-test)). The coefficients of the logit model were obtained by 242 
estimating the a priori model, i.e. the model with the utility function that seemed most 243 
appropriate when planning the DCE, and subsequently dropping the non-significant 244 
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model terms until we obtained a final model in which all effects had significant 245 
explanatory value at the 5% level. Models were fitted using the JMP 13 Pro Choice 246 
platform (based on 10,000 iterations, with the last 5000 used for estimation) 247 
assuming normally distributed parameters with no correlation between the attributes. 248 
Combining the main and interaction effects, this model allows calculating the 249 
additional utility of a vaccination program generated per additional health effect, i.e. 250 
per type of effect per age group (see the nine variations in Table 3). The 95% 251 
confidence intervals for the equity weights were estimated using the Delta method 252 
[52].  253 
 254 
We investigated heterogeneity in respondents’ preferences in two ways. First, by 255 
exploring the influence of the observed respondent characteristics on the average 256 
preferences and, second, by studying the unobserved preference heterogeneity by 257 
means of a hierarchical cluster analysis on the subject-specific estimates resulting 258 
from the Hierarchical Bayes approach. We favoured this two-stage modelling method 259 
as it performs equally well as one-stage modelling methods such as latent class 260 
modelling [53] while enabling us to parsimoniously derive the preference weights and 261 
their 95% confidence intervals.     262 
 263 
3. Results 264 
 265 
3.1 Response 266 
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A total of 1546 respondents out of 1950 (79%) who were sent the questionnaire 267 
completed it, of which 47 (3%) indicated that the questions were too difficult or their 268 
answers invalid, leaving 1499 questionnaires for analysis. Our final sample was 269 
sufficiently representative of the UK population in terms of gender, family size, socio-270 
economic status and education level (Table 2).  271 
 272 
(insert Table 2) 273 
 274 
3.2 Main effects and calculated weights 275 
Across all questionnaires, respondents made a total of 22,485 choices between 276 
vaccination programs. There was no significant effect observed of which of the three 277 
survey versions a participant received. Respondents did not systematically choose 278 
the program with the highest overall public health impact, i.e. the total of all 279 
prevented cases including direct, herd and side effects. In fact, only 99 respondents 280 
(6.6%) consistently opted for the most effective program in all of their choice sets. 281 
However, about half the respondents (738/1499) chose the most effective alternative 282 
in at least 70% of their choices, indicating that the total effect on the disease burden 283 
is important, but not the only factor in prioritizing vaccination programs.  284 
Table 3 presents an overview of the incremental utility of the main effects and 285 
interactions. The vaccination program that was least preferred (i.e. yielding minimum 286 
utility) was one that targeted the elderly (65-75y), generated the lowest number of 287 
prevented cases, the highest number of side effects, and the lowest number of cases 288 
prevented via herd protection in unvaccinated adults. The most preferred program 289 
(i.e. yielding maximum utility) was one that targeted children, generated the highest 290 
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number of prevented cases, the lowest number of side effects, and the highest 291 
number of cases prevented via herd protection in newborns.  292 
 293 
(insert Table 3) 294 
 295 
Using the same logit model, we then calculated preference weights for each effect 296 
type per age group. These weights act as a multiplicative factor to transform identical 297 
clinical symptoms into health effects with equal value in the public’s view. We 298 
compared the additional utility of a vaccination program that is generated through 299 
preventing one specific disease case relative to the utility gained through directly 300 
preventing a single disease case via vaccinating a child (Figure 3). These 301 
preference weights reveal important patterns. First, preventing side effects of 302 
vaccination was highly preferable to preventing natural infections, even though the 303 
symptoms were equal in length and severity. The mean weight for side effects 304 
across all ages was -2.93, meaning that avoiding one vaccine-induced infection was 305 
weighted equally to avoiding around three natural infections among children. This 306 
finding was consistent whether side effects occurred in children (-2.95 (95% CI: -307 
3.21; -2.69)), adults (-3.16 (95% CI: -3.51; -2.81)) or the elderly (-2.68 (95% CI: -308 
2.98; -2.37)). Second, respondents preferred vaccination programs that prevented 309 
disease among newborns and children compared with those for adults and the 310 
elderly, even though the prevented disease burden was similar. One episode 311 
prevented in a newborn via herd protection was considered about twice as valuable 312 
as directly protecting an adult via vaccination. Third, the extent to which respondents 313 
preferred protecting adults and the elderly depends on the type of benefit conferred 314 
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by the program. Direct effects were the preferred mode of protection for adults 315 
whereas herd effects were preferred for the elderly. Reducing disease burden by 316 
directly vaccinating adults (aged 30-50 years) was weighted equally to reducing 317 
disease burden in the elderly (aged 80+ years) via herd effects [0.75 (0.64; 0.85) 318 
compared to 0.67 (0.58; 0.76), respectively]. In contrast, reducing disease burden in 319 
adults (aged 30-50 years) by herd effects counted equally to reducing disease 320 
burden in elderly (aged 65-75 years) directly via vaccination (0.12 (0.03; 0.20) 321 
compared to 0.16 (0.06; 0.25), respectively).  322 
 323 
(insert Figure 3) 324 
 325 
From these results, we also calculated the number of infections needed to avert in 326 
order to obtain equal utility as that from protecting 100 children directly via 327 
vaccination (Table 4). Avoiding 100 infections in children via vaccination was 328 
considered equivalent to protecting 632 elderly (65-75 years) or 134 adults. In turn, 329 
these outcomes were equivalent to protecting 71 newborns, 865 adults or 150 330 
elderly (>80y) via herd protection. Similarly, a vaccination strategy reduces its utility 331 
by causing side effects. Avoiding 34 side effects in children generates the same 332 
utility as preventing 100 natural infections among the same age group.  333 
 334 




Figure 4 illustrates the significant interaction in our model between the age of the 337 
vaccinated group and the age of the herd protection recipients (see Table 3). This 338 
interaction must be understood as the additional utility that is given to (or taken away 339 
from) a vaccination program depending on the particular combination of age groups 340 
that are involved, regardless of the magnitude of direct, herd or side effects that are 341 
being generated. It presents the attractiveness of particular intergenerational 342 
vaccination strategies. Whereas a CEA perspective would consider all possible age 343 
combinations equally attractive (as long as they lead to the same number of 344 
infections prevented), our sample had clear intergenerational preferences over 345 
vaccination strategies. Any age group was deemed acceptable to vaccinate when 346 
there were herd protection benefits for newborns. To generate herd protection for 347 
adults, children were the most attractive age group. To generate it to protect the 348 
elderly >80, adults were deemed most appropriate. The least attractive 349 
intergenerational combination was vaccinating elderly 65-75 years while generating 350 
herd protection in adults 30-50 years. The most attractive age combination was 351 
vaccinating children while generating herd protection in newborns.  352 
 353 
(insert Figure 4) 354 
 355 
3.3 Preferences across disease types and respondents 356 
As shown in Appendix D, our results remained robust across all four different 357 
disease types: the equity weights were statistically equivalent, regardless of whether 358 
the condition was mild vs. severe or acute vs. chronic (indicated by a non-significant 359 
interaction effect in our model between the attributes and the disease type). Also, the 360 
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appendix illustrates that our findings also remained robust across most respondent 361 
characteristics: gender, age, occupation, level of education, urban-rural, socio-362 
economic background, experience with severe illness or parental status. Although 363 
individuals with a low degree of vaccine hesitancy (indicated by high values on the 364 
‘vaccine hesitancy scale’ (VHS) [50]) attributed less importance to side effects 365 
(p<0.0001), this effect was relatively small (a 10 unit increase in the VHS score (on a 366 
scale from 10 to 50) led to a 10% decrease in absolute magnitude of the utility for 367 
side effects (~0.03)).  368 
The hierarchical cluster analysis of the individual preferences (see methods) 369 
revealed two distinct groups of respondents: one group (N=564, Cluster 1) who 370 
attached almost no importance to the number of side effects (with a mean weight of -371 
0.91 for side effects) and a larger group (N=935, Cluster 2) who valued this attribute 372 
fairly highly (with a mean weight of -4.40) (Table 3). This clustering explains the 373 
relatively high variation across respondents for the weight estimate for side effects 374 
(the standard deviation to mean absolute value ratio of 0.043 for side effects is 375 
almost twice the ratio for direct and herd effects). We used a logistic regression to 376 
determine predictors of cluster membership. Cluster 1, who attached almost no 377 
importance to the number of side effects, was characterized by high values on the 378 
VHS, indicating little hesitancy (p<0.0001). On the other hand, cluster 2, who valued 379 
side effects more highly, was characterized by higher degrees of hesitancy on the 380 
VHS. However, the predictive power of this association for membership of the group 381 
was small (McFadden’s pseudo R2=0.6%), implying that there is much unexplained 382 




  385 
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4. Discussion 386 
In this study, we used a discrete choice experiment to analyse and quantify how the 387 
public values the outcomes of vaccination programs. We observed several general 388 
preference patterns, which were robust across different lengths and severities of 389 
disease and respondent characteristics (socio-economic background, age, education 390 
and parenthood). We observed that most respondents did not make choices purely 391 
based on how to minimize the number of infections. In particular, individuals, on 392 
average, weighted one averted instance of a side effect equal to about three similarly 393 
severe natural infections in children and weighted one averted health outcome in 394 
children up to six times more than preventing similarly severe health outcomes in the 395 
elderly. Interestingly, our study has disentangled this latter phenomenon from the 396 
type of effect as we observed a different weight given to protecting older people 397 
depending on whether the benefits were directly vs. indirectly received. Our results 398 
support a duty of care principle to provide herd protection for the elderly and an 399 
aversion to protecting adults who are better able to protect themselves. The weight 400 
given to side effects when evaluating a vaccination program was divisive, splitting 401 
our sample into two clusters.  402 
Our study, as far as we are aware, is the first of its kind to quantify the important 403 
social value judgements that need to be made in vaccine funding decisions. 404 
Although this limits comparability, our findings are in line with what can be learned 405 
from other study domains. The finding that individuals weighted one averted instance 406 
of a side effect equal to about three similarly severe natural infections in children can 407 
be explained with general theory on decision-making. For instance, well-documented 408 
psychological phenomena such as ‘loss aversion’ [55] (overvaluing risks and losses 409 
over opportunities and gains), the ‘act-omission bias’ [56] [judging the effects of an 410 
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act (becoming vaccinated) differently from identical effects resulting from an 411 
omission (becoming infected)], or ‘hyperbolic discounting’ [57] [overvaluing the 412 
present (in which side effects occur) over the future (in which disease prevention will 413 
occur)] suggest that people put an extraordinary weight on side effects when 414 
evaluating a vaccination strategy. Moreover, also empirical studies that have 415 
investigated people’s (stated) choices about whether or not they would personally 416 
become vaccinated with a particular vaccine (e.g. [43, 58]) generated findings that 417 
highlight the extraordinary weight of side effects. The preference given to health 418 
benefits in younger people (newborns and children), up to six-fold, is also in line with 419 
related studies on ‘ageism’ in other contexts of healthcare priority-setting (reviewed 420 
in [59] and discussed elsewhere, e.g. [60, 61]).  421 
It is important to study which aspects of health policy choices matter most to the 422 
public. This is especially true in vaccination where public trust, goodwill and 423 
participation are sensitive and key to success [62]. There is a growing concern that 424 
public and political trust in scientific evidence is eroding, particularly in the context of 425 
vaccination [63-65]. By being aware of the sensitivities around vaccination, decision 426 
makers can understand and address some of the root causes of vaccine hesitancy, 427 
adapt to concerns of the population and improve responses in communication 428 
strategies.[66] Our findings provide empirical evidence on how to set vaccine 429 
priorities in line with public preferences. There is an important debate over the extent 430 
to which the public’s opinion should drive resource allocation in healthcare (see e.g. 431 
[67, 68]). But, many believe that the values of the public, who pays for healthcare, 432 
should at least somehow be acknowledged in the decision-making process. In the 433 
context of vaccination, where public support and participation is key to success, this 434 
concern becomes particularly crucial. Therefore, our results can be useful additions 435 
20 
 
to vaccine appraisals. They can provide guidance in specific epidemiological cases 436 
where CEA does not provide the answers needed. For instance, our results would 437 
suggest that, despite their attractiveness in terms of cost-effectiveness, the public 438 
may not support a childhood influenza vaccination program that mainly benefits 439 
adults or elderly [69], because preventing side effects in vaccinated children is 440 
preferred over preventing disease burden among adults and elderly. Furthermore, 441 
our study suggests that a childhood varicella-zoster vaccination program, in the case 442 
that it protects children against varicella disease at the expense of increased zoster 443 
in the elderly (the ‘exogenous boosting hypothesis’), might be justifiable. In contrast, 444 
previous analyses where QALY losses for children are weighted equally to those for 445 
the elderly find that the increased burden in the elderly offsets the QALY gains in 446 
children and determine the program not cost-effective [23, 70].  447 
Our results can also be directly incorporated into economic evaluations as sensitivity 448 
analyses to better align the underlying assumptions of CEA with the values of the 449 
population. Our estimated preference weights can be used in decision-analytic 450 
models as a parameter to weight QALYs or infections according to their ‘social 451 
value’. This would re-adjust the (equal) weight that QALYs receive in CEA according 452 
to how important people think that the age of the QALY-recipient is and whether the 453 
benefit was generated through direct protection, herd immunity or (avoiding) side 454 
effects. There is an increased interest in such ‘extended’, ‘distributive’ or ‘equity-455 
weighted’ economic evaluation (see e.g. [7, 34, 71-76]), but, to our knowledge, such 456 
studies do not exist for the evaluation of vaccines. Our estimates are developed 457 
particularly for this context, and provide an opportunity to do so.  458 
There are several limitations. We did not include any mortality effects, nor did we 459 
include a difference in severity between the three vaccine effects, even though this 460 
21 
 
would be more realistic (as side effects of vaccines are usually milder than the 461 
disease being prevented). We chose not to include these aspects because we 462 
wanted to avoid increasing the complexity of the survey and reducing the validity of 463 
the respondents’ answers by adding a second disease profile. Also, keeping the 464 
disease outcome constant over age groups and effects enabled trade-offs that were 465 
wholly reflective of the preference between age groups and effects instead of also 466 
reflecting additional considerations about disease severity. We also chose to present 467 
the number of side effects rather than its complement the number of vaccinated 468 
people without side effects. This framing may have played a role in the observed 469 
weight for side effects. The alternative framing would probably have drawn less 470 
attention to side effects and might have generated smaller weights. We however 471 
wanted people to make explicit trade-offs between side effects with protective 472 
benefits and chose for the more direct framing. Using the alternative is a suggestion 473 
for further research.  Also, we used generic disease profiles based on a description 474 
in EQ-5D terms to minimize respondents making personal associations to the 475 
disease and vaccine when we would have named the diseases (e.g. ‘flu’ or 476 
‘whooping cough’), but this may also have increased the level of abstraction and 477 
reduced the level of personal involvement. A suggestion for further research is to 478 
repeat our study with named diseases and to test whether our finding that the 479 
disease profile did not matter to people’s preferences is confirmed. Another limitation 480 
is that, while our sample was broadly representative of the UK population, it was 481 
recruited from an online panel where membership may be associated with 482 
unobserved characteristics (e.g. interest in technology).  483 
In conclusion, our study demonstrates clear and robust preference patterns in how 484 
people value the impact of vaccination programs. A large majority of respondents 485 
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had a strong preference to minimize side effects and to prevent disease among 486 
newborns and children. Our observations provide quantitative evidence about public 487 
preferences around important and sensitive but neglected trade-offs in vaccine policy 488 
decision-making, and can hopefully inspire further research and discussion.   489 
 490 
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Table 1. Attributes and levels used in the DCE 653 
Attribute Level 
Age of vaccinated group (N=100 000) Children (3 months -  3 years) 
Adults (30-50 years) 
Elderly (65-75 years) 
Disease episodes prevented in 




Number of vaccine-induced side-effects 100 cases 
300 cases 
500 cases 





Age of people receiving herd protection Newborns (<3 months) 
Adults (30-50 years) 
Elderly (>80 years) 
 654 




Table 2: Respondent characteristics. 657 
 Sample UK population* 
Total recruited 1546   
Excluded for analysis 47  
Included in the analysis 1499 (100%)  
Gender   
Male 703 (47%) 49% 
Female 796 (53%) 51% 
Age (years)   
20-29 296 (20%) 13% 
30-39 285 (19%) 13% 
40-49 288 (19%) 14% 
50-59 308 (21%) 13% 
60 and over 322 (21%) 23% 
Living in a city with more than 10,000 
inhabitants  
1011 (67%) 83% 
Social grades based on the profession of the 
highest paid household member  
  
A (upper middle class) 85 (6%) 4% 
B (middle class) 297 (20%) 23% 
C1 (lower middle class) 385 (26%) 27% 
C2 (skilled working class) 330 (22%) 21% 
D (working class) 72 (5%) 16% 
E  (non-working) 330 (22%) 9% 
Education level   
No qualifications 48 (3%) 15% 
Secondary education  322 (21%) 14.2% 
Post-secondary education 288 (19%) 14.5% 
Vocational qualification 254 (17%) 20.3% 
Undergraduate degree, Post-graduate 
degree & Doctorate  




*UK population data 2016: Office for National Statistics https://www.gov.uk/government/publications  659 















Not sure 2 (0.1%) / 
Having children   
No children 585 (39%) 42% 
Children aged 0-4 years 168 (11%) 42%** 
Children aged 5-20 years 358 (24%) / 
Children aged over 20 years 388 (26%) 15% 
Exposure to poor health    
Participant affected by poor health 407 (27%)  
Close friends or family of the participant 
affected by poor health 
470 (31%)  
Neither participant nor close friends nor 
family affected by poor health 




Table 3. Attributes that affected respondent choices, based on panel mixed logit model estimates (means and standard 676 
deviations) with p-values from likelihood ratio (LR) tests for significant attribute effects.  677 
Model term Posterior mean Posterior std dev Subject std dev P-value 
Cases prevented in unvaccinated by herd effects  
(per 1000 cases) 0.715 0.018 0.101 <0.0001 
Cases prevented in vaccinated by direct effects (per 1000 
cases) 0.619 0.018 0.100 <0.0001 
Cases of side effects in vaccinated (per 100 cases) -0.285 0.012 0.110 <0.0001 
Age of unvaccinated  
 
 
[Newborns <3m] 0.614 0.048 0.090 <0.0001 
[Adults 30-50y] -0.597 0.043 0.105   
[Elderly >80y] -0.017  NA  NA   
Age of unvaccinated*Cases 
prevented in vaccinated by 
direct effects 
[Newborns <3m] -0.043 0.009 0.054 <0.0001 
[Adults 30-50y] 0.071 0.009 0.041   
[Elderly >80y] -0.028  NA  NA   
Age of vaccinated  
 
 
[Children 3m-3y] 0.305 0.040 0.063 <0.0001 
[Adults 30-50y] 0.142 0.048 0.062   
[Elderly 65-75y] -0.446  NA  NA   





[Newborns <3m]* [Children 3m-
3y] -0.131 0.036 0.053 <0.0001 
[Newborns <3m]* [Adults 30-
50y] -0.210 0.041 0.065   
[Newborns <3m]* [Elderly 65- 0.341  NA  NA   
30 
 
Note: Mean estimates corresponding to the last level of an attribute, either as a main effect or involved in an interaction, are italicized and calculated as minus 678 






[Adults 30-50y]* [Children 3m-
3y] 0.250 0.052 0.044   
[Adults 30-50y]* [Adults 30-
50y] -0.079 0.049 0.045   
[Adults 30-50y]* [Elderly 65-
75y] -0.171  NA  NA   
[Elderly >80y]* [Children 3m-
3y] -0.119  NA  NA   
[Elderly >80y]* [Adults 30-50y] 0.289  NA  NA   
[Elderly >80y]* [Elderly 65-75y] -0.170  NA  NA   
Age of vaccinated*Cases of 
side effects in vaccinated 
[Children 3m-3y] -0.032 0.008 0.040 <0.0001 
[Adults 30-50y] -0.037 0.009 0.044   
[Elderly 65-75y] 0.069  NA  NA   
Age of unvaccinated*Cases 
prevented in unvaccinated by 
herd effects 
[Newborns <3m] 0.052 0.009 0.048 <0.0001 
[Adults 30-50y] -0.005 0.008 0.043   
[Elderly >80y] -0.047  NA  NA   
Age of vaccinated*Cases 
prevented in vaccinated by 
direct effects 
[Children 3m-3y] 0.051 0.010 0.044 <0.0001 
[Adults 30-50y] -0.032 0.009 0.037   
[Elderly 65-75y] -0.019  NA  NA   
31 
 
Table 4. Number of infections to prevent to gain equal utility, with 95% 680 
confidence intervals.  681 
Age group of 
vaccine effect 
Direct effects Herd effects Side effects 
Newborns  
(<3 months) 




(3 months – 3 years) 
100  
[index] 
NA -34  
[-37; -31] 
   Cluster 1: -221 [-340; -102]  








 [-35; -28] 
   Cluster 1: -72 [-93; -51] 





NA -37  
[-42; -33] 
   Cluster 1: -113 [-163; -64] 
   Cluster 2: -25 [-27; -22]  
Elderly  
(>80 years) 
NA 150  
[130; 169] 
NA 
Note: Cluster 1 and 2 have 564 and 935 respondents, respectively; NA refers to combinations of 682 
attribute levels not included in the choice profiles. 683 
  684 
32 
 
Figure 1. Example of a choice set. 685 
 686 
Figure 2. Schematic representation of the different arms of the questionnaire. 687 
For each disease stratum, there was also an equal sampling over the socio-688 
economic groups (25% A+B; 25% C1; 25% C2; 25% E+D). 689 
 690 
Figure 3. Utility weights representing public preferences for identical health 691 
outcomes with different attributes, with 95% confidence intervals. 692 
 693 
Figure 4. Intergenerational preferences: interaction effects between the age 694 
group vaccinated and the age group receiving herd protection effects. 695 
Marginal utility values consist of main effects of the attributes involved and 696 
their interaction effect..  697 
 698 
 699 
Figures (NO AUTHOR DETAILS)
Mild / 9 days Mild / 160 days Severe / 9 days Severe / 160 days 
125 





Total 1500 participants 
DCE survey 1 
DCE survey 2 
























































































































































Herd effects Newborns (<3 months)
Herd effects Adults (30-50 years)
Herd effects Elderly (>80 years)
Figures (NO AUTHOR DETAILS)
  
Electronic Supplementary Material (online publication only - NO AUTHOR DETAILS)
Click here to download Electronic Supplementary Material (online publication only - NO AUTHOR DETAILS): Appendix 20180315.docx
Ethical approval 
We obtained informed consent from all respondents and ethical approval of the study from 
the Ethics Committee of the London School of Hygiene & Tropical Medicine (Ref 10335). We 
conducted the research in accordance with the Code of Conduct of the Market Research 
Society, which ensured that information is collected for research purposes only, is kept 
confidential, and respondent anonymity is guaranteed.  
Acknowledgements 
We thank Shane Palmer and Jas Gidda of Vision One (www.visionone.co.uk) for their 
supportive comments and running the study. 
Funding 
The data collection and the salary of KEA, MJ and AJVH were supported by the National 
Institute for Health Research Health Protection Research Unit (NIHR HPRU; HPRU-2012-
10096) in Immunisation at the London School of Hygiene & Tropical Medicine in partnership 
with Public Health England (PHE).  
The views expressed are those of the authors and not necessarily those of the NHS, the 
NIHR, the London School of Hygiene & Tropical Medicine, and the Department of Health or 
Public Health England. The funders have had no input to this study in terms of study design, 
analysis of the data or writing of the manuscript. 
*Ethics approval/Statement EA not required
